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ABSTRACT
Human immunodeficiency virus type 1 (HIV-1) chronically infects approximately 30
million people worldwide. HIV-1 has become one of the most difficult viral infections to
treat due to its high mutability and emerging drug resistance. Critical to our development
of more effective therapeutic treatments, we must better understand the HIV life cycle in
order to reveal better targets for drug development. Thus, the purpose of this work was to
investigate the role of autophagy, a cellular homeostatic mechanism capable of
eliminating intracellular pathogens, in HIV-1 infection of two relevant hosts, the human
and the Old World non-permissive primate, the rhesus macaque.

The ability of

autophagy to eliminate HIV-1 in these two species was compared with the objective of
identifying why rhesus macaques efficiently eliminate HIV-1 and humans do not. Here
we report that human cells have lost autophagic protection against HIV, and identify a
role for autophagy in supporting HIV-1 biogenesis and egress from human macrophages.
We further identify the rhesus macaque restriction factor, rhesus TRIM5α, as a major
player in targeting HIV-1 for degradation through p62-dependent recognition and capture
by the autophagy machinery.
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CHAPTER 1

INTRODUCTION
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Autophagy acts as a defense against intracellular pathogens
Autophagy is a multi-purpose homeostatic process whereby cells gather intracellular
components in a double membrane compartment and target the contents for degradation
through convergence with the lysosomal pathway. First called "autophagy" by Cristian
de Duve in 1963, the double membrane compartment was identified as a lysosome related
structure containing mitochondria, endoplasmic reticulum, and dense structures indicative
of cytosolic proteins and ribosomes. De Duve went on to show that glucagon treatment
of liver cells induced the formation of autophagic vacuoles which could fuse with
lysosomes [1]. Despite this early discovery of autophagy, intensive research on this
important cellular pathway was not part of the research landscape until the identification
of autophagy genes in yeast about 15 years ago [2-4]. Since that time, research on the
mechanisms underlying autophagy have increased exponentially, yet important aspects of
the autophagy pathway still remain unclear. For example, despite efforts to determine the
origin of the membrane forming the autophagosome, the basic unit of the autophagy
pathway consisting of a double membrane vacuole, it is still unresolved.

Three types of autophagy have been described.

The first and primary type,

macroautophagy, hereafter referred to simply as autophagy, has been researched
primarily in mammalian cells. It is characterized by the large-scale engulfing of items in
a double membrane vacuole.

The second type, primarily studied in yeast, is

microautophagy. Microautophagy is a process of budding directly into the lysosome.
This type of autophagy allows only for the degradation of small amounts of cytoplasm.
The third type of autophagy, called chaperone mediated autophagy (CMA), has also been
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researched mainly in yeast. In CMA, proteins are directly translocated into the lysosome
by heat shock cognate protein 71kDa (hsc70).

Autophagy can be separated into three stages: initiation, elongation, and maturation. In
initiation (Fig. 1.1), autophagy induction is regulated by two, seemingly independent,
signaling pathways. The first is centered around Beclin 1, a component of the class III
PI3K complex also containing human vacuolar protein sorting 34 (hVPS34, the class III
PI 3-kinase) and its regulatory subunit p150, and the second is centered around
mammalian target of rapamycin (mTOR), which acts as a suppressor of autophagy
initiation. Beclin 1 is believed to promote colocalization of the components necessary for
autophagosome formation [5] and its association with hVPS34 can be positively
regulated by autophagy protein 14 (Atg14) and negatively regulated by Bcl-2 [6-8] as
well as other factors, while mTOR inhibits Unc-51-like kinase 1 (Ulk1) activation
through phosphorylation thereby preventing Ulk1-mediated induction of autophagy [9].

Once either signaling pathway is activated, nascent membrane will begin to form in a
crescent shape known as a phagophore. It is commonly believed that the phagophore can
initiate directly adjacent to autophagic targets [10]. The curvature of the phagophore is
assisted by proteins encoded by autophagy (Atg) genes, specifically the Atg12-5/16L
complex, covering the convex side of the initiating membrane.

Atg5 and 12 are

conjugated by the action of two other autophagy factors, Atg7 and Atg10, then associate
hydrophobically with Atg16L [11].

Both the convex and concave sides of the

phagophore are coated externally with a protein called LC3. LC3 exists in two forms, an

3

Figure 1.1. Initiation. Phagophore formation is centered around two proteins, Beclin 1 and mTOR.
Beclin 1 forms a complex with hVPS34 and its regulatory subunit p150. Initiation of autophagy by
Beclin 1 can be positively regulated by Atg14 and negatively regulated by Bcl-2. mTOR negatively
regulates Ulk1, preventing its association with Ulk2 and suppressing autophagy initiation. The outer
surface of the phagophore is covered by Atg12-5/16L protein complexes, which facilitate curvature of
the phagophore. Atg7 assists in formation of the Atg12-5/16L complex. Around the entire
phagophore is LC3 II, which is recycled on and off the membrane by the activity of Atg7 and Atg4,
respectively.

unlipidated, cytosolic form called LC3 I, and a phosphatidylethanolamine lipidated,
membrane bound form called LC3 II. These two forms of LC3 can be used to indicate
the state of autophagy. An increased rate of conversion from the LC3 I form to the LC3
II form indicates that there is an enhancement or induction of autophagy from basal
levels. In the presence of maturation inhibitors, LC3 II will not be degraded and its
accumulation can be a positive indicator of treatment success.

In elongation (Fig. 1.2), the phagophore continues to grow around its cargo ending with
fusion and closure of the double membrane structure into what is now called the
autophagosome. Trapped within the autophagosome are LC3 II and the cargo, along with
any autophagy adaptors or tags (for example, polyubiquitin, discussed later in this chapter
4

Figure 1.2. Elongation. The phagophore grows around the target (Cargo) for autophagic capture. In
this example, the cargo is tagged with polyubiquitin chains (red, sequential circles) which are
recognized by an autophagy adaptor (yellow circles), and in turn, associate with LC3 II on the
phagophore membrane, thus resulting in recognition. After fusion and closure of the phagophore
membrane, the structure is now called an autophagosome, where LC3 II, cargo, polyubiquitin, and
autophagy adpators can be trapped inside. LC3 II on the outside of the autophagosome can be
removed by the activity of Atg4 and recycled back into the cytosol as LC3 I.

and in Chapter 5) that may have been associated with the cargo during recognition and
capture. The recognition and capture of targets for autophagic degradation, which occur
during initiation and elongation, is mediated by a variety of autophagy cargo adaptor
proteins. The first adaptor protein to be recognized was
p62, also known as sequestosome 1 [12] (for a review and
explanation of the domains of p62, see Fig. 1.3 and G1).
Before the discovery of p62's role in autophagy, it was
originally found in complex with aggregates in several
diseases such as Paget’s disease of bone, Parkinson’s
disease,

Huntington's

disease,

and

hepatocellular

carcinoma. Subsequent to the discovery of p62, other
autophagy

adaptor

proteins

have

been

including Nix, NBR1 [13], and ALFY [14, 15].
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identified,

Figure 1.3. p62 and domains.
P62, also called sequestosome
1, is an autophagic adaptor
protein involved in recognition
of cytoplasmic targets, typically
aggregated
proteins,
for
autophagy.
Specifically
recognizes the polyubiquitin tag
of proteins through its UBA
domain and associates with
LC3 through it LIR domain.
PB1
domain
allows
dimerization with itself and
other autophagy adaptors. The
ZZ type zinc finger is involved
in other signaling functions of
p62.

The last stage of autophagy is maturation. During maturation (Fig. 1.4), lysosomes fuse
with the autophagosome, where the inner membrane, cargo, and LC3 II proteins that were
trapped inside are degraded by acidification and protease activity. The resulting basic
cellular components are believed to be recycled back into other cellular pathways as
needed for protein production, organelle formation, and other homeostatic processes.
Recently, Beclin 1 has been shown to be involved in regulating this stage of autophagy as
well. Here, Beclin 1 association with hVPS34 can be positively regulated by UVRAG
and negatively regulated by Rubicon [6, 7].

Consequent to the ability of autophagy to regulate intracellular composition, the
autophagy mechanism has been exploited in the management of a broad spectrum of
diseases and physiological states including cancer, aging, neurodegeneration,
inflammation and immunity. Autophagy's role in immunity includes both adaptive and
innate immunity. In adaptive immunity, autophagy has been found to affect Th1 versus
Th2 differentiation of the T cell response. It has also been shown to assist in antigen
loading of MHC class II molecules for presentation. In innate immunity, autophagy has
been shown to be involved in direct elimination of pathogens, and to function as both an
effector and a regulator of the innate immunity machinery through interactions with tolllike receptors (TLR) and antigen presentation through MHC class I [16, 17].
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Figure 1.4. Maturation. The autophagosome formed during elongation will fuse with lysosomes,
now called an autolysosome, resulting in degradation of the inner membrane and contents trapped
inside. This process of maturation can be controlled by the Beclin 1, hVPS34, p150 complex through
positive and negative regulation of this complex by UVRAG and Rubicon.

Studies on autophagy's role in elimination of pathogens have shown that autophagy can
act as a cell-autonomous defense against intracellular pathogens, whereby invading
microbes or their toxic products can be targeted by autophagy and degraded through
fusion with lysosomes.

Specifically, studies involving the knock down of essential

autophagy genes have been shown to aggravate infections by vesicular stomatitis virus,
tobacco mosaic virus, Staphylococcus aureus, Listeria monocytogenes, group A
Streptococcus, Bacillus anthracis, Helicobacter pylori, Vibrio cholerae, and others [5].

However, in the case of pathogenic species, certain microbes are able to avert the
degradative stages of autophagy.

These successful pathogens have evolved anti-

autophagic factors to protect against autophagic clearance. One of the first pathogens of
this kind to be studied was herpes simplex virus type 1 (HSV-1) [18]. Orvedahl et al.
showed that the HSV-1 neurovirulence protein ICP34.5 binds to and inhibits Beclin 1,
thereby preventing proper clearance of the herpes virus in brain tissue and leading to
lethal encephalitis in a mouse model.

Yet other studies have shown that certain
7

pathogens can use autophagy to assist in replication. For example, Jackson et al. showed
that induction of autophagy during poliovirus infection actually increases production, as
well as release of the virus [19]. They went on to hypothesize that autophagic membrane
was being hijacked by the poliovirus as a source of membrane for envelope formation
and as a site of assembly for biogenesis. These reports on autophagy involvement in
pathogen life cycles led us to hypothesize that human immunodeficiency virus type 1
(HIV-1) intersects the autophagy pathway.

Elimination of HIV by autophagy should be escaped by the virus as a requirement
to developing AIDS
Human immunodeficiency virus type 1 (HIV-1)
is

the

most

common

cause

of

acquired

immunodeficiency syndrome (AIDS) in humans
(Fig. 1.5, showing structure and components of
HIV). HIV-1 is believed to have evolved from
simian immunodeficiency virus (SIV) variants
that recombined in chimpanzees, while HIV-2 is
believed to have evolved more directly from
sooty mangabey monkeys [20]. Two important
elements in the pathogenicity of the pandemic
strain of HIV-1 (group M) that are generally
impaired in the non-pandemic strains of HIV,
including HIV-2, are the ability of the virus to (i)
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Figure 1.5. HIV structure and
components. The HIV virion is an
enveloped, double-stranded RNA
virus. The envelope of HIV contains
glycoprotein (gp) 120 heads and
gp41 stalks. Inside the envelope is
the matrix of the virus, composed of
p17 (derived from HIV Gag)
structural protein. Inside the matrix
of the virus is the core, composed of
p24 capsid protein (also derived
from Gag) forming a Fullerene core
shape.

down-regulate antagonizers to the budding of HIV-1, CD4 and tetherin, despite the
requirement for CD4 as the primary receptor for virion fusion and entry, and (ii) an
evolved loss of the viral protein Nef to dampen immune activation through downregulation of surface CD3 [21]. The enhanced budding allows the virus to promote hostwide infection more efficiently in the face of the greater immune activation.
Paradoxically, the inability of Nef to down-regulate CD3 in pathogenic strains of HIV
coincides with the expression of the viral protein Vpu, which is also responsible for the
down-regulation of surface tetherin. Viruses that encode Vpu almost always encode a Nef
that is deficient for down-regulation of CD3 [21].

Much of the pathogenicity of HIV-1 has been attributed to its regulator protein Nef.
Perhaps the best demonstration of the pathogenicity enhancing effects of Nef have been
in studies showing that Nef-deficient virus in vivo results in an attenuated strain of HIV,
marked by reduced yields of the virus in the infected individual's blood plasma [22]. The
most well-known of these studies has been the Sydney Blood Bank Cohort, where 8 longterm non-progressors of HIV, all containing mutations in their Nef alleles, were followed
for more than 20 years. For more than 17 of these years these individuals had nearly
undetectable plasma viral loads reflecting the impaired production of HIV deleted for Nef
[22]. Studies on this cohort and others have hypothesized that the decreased viral load
seen in these patients is due to a defect in viral replication as assisted by the Nef protein.
Several follow-up studies sought to investigate the exact role of Nef in viral pathogenesis,
with the majority of these indicating that Nef's effects on maintaining viral load are
cumulative and primarily based on two effects: first, in Nef enhancing virion release and
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second, in Nef enhancing infectivity of those particles released. These activities would
result in an enhanced host-wide infection through increased cellular transmission.

The most in-depth studies on the effect of Nef in promoting viral release to date have
shown that Nef specifically mediates the following activities: (i) down-regulation of
CD4, thereby preventing the CD4-mediated blockade of viral assembly and budding at
the plasma membrane (further discussed below), (ii) the bridging of the HIV structural
protein precursor GagPol (cleaved into Gag, which is further processed into structural
proteins, and polymerase) to the ESCRT machinery, through AIPI/ALIX, to assist in HIV
egress [23], and most recently, (iii) implications for Nef in enhancing the incorporation of
fusogenic cholesterols into viral particles which could assist in budding, as well as
subsequent fusion of the virion [24, 25]. In addition to enhancing release, and perhaps
even fusion events, the gain in infectivity by Nef has also been shown to include altered
trafficking of cellular components necessary for viral replication, altered trafficking of
cellular components necessary for survival of infected cells, and trafficking and assembly
of viral components necessary for viral replication [26].

One of the earliest studies on how CD4 impairs release of viral particles showed that
CD4 can directly interact with and bind envelope proteins at the plasma membrane and
prevent proper budding and egress of virions from the infected cell [27]. From this study,
it was demonstrated that down-regulation of surface CD4 from the plasma membrane
during infection required the presence of Nef. It had also been shown about this time that
Nef could also interact with the endocytic machinery through interaction with adaptor
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protein (AP) complexes [28]. Thus, it was hypothesized that Nef bridged CD4 with the
endocytic machinery via interaction with AP complexes, thereby mediating its
endocytosis from the plasma membrane. After endocytosis of CD4, Nef then mediates its
targeting to lysosomes through interaction with β-COP [29]. Because many of the factors
involved in endocytosis are now known to also be involved in autophagy, it is therefore
tempting to suggest that vesicular re-trafficking by Nef may represent a conserved
mechanism by which Nef manipulates autophagy. Indeed, it has been recently shown
that adaptor protein 2 (AP-2), the same AP now known to be required for Nef-mediated
CD4 down-regulation [30], is involved in the endocytic delivery of plasma membrane to
autophagy for autophagosome biogenesis [31].

The possible role of autophagy in HIV-1 pathogenesis was first investigated by Codogno
and Biard-Piechaczyk. In their article published in 2006, the two authors showed that an
interaction between the HIV envelope and CD4+ T cell co-receptor CXCR4 induced
autophagy-mediated cell death [32]. The authors suggested that this may reveal how
uninfected bystander CD4+ T cells are killed during the development of AIDS.
Subsequent to this publication, a study published in 2008 identified the involvement of
over 250 host genes as essential factors for HIV replication in a siRNA genomic screen
[33]. The authors, Brass et al., called these genes HIV dependency factors (HDFs). Of
the over 250 HDFs Brass identified were four autophagy genes: Atg 7, Atg 8, Atg 12, and
Atg16L2. Because the cells this study used in the genomic screen were not primary
targets of HIV infection, it is possible that more or different autophagy genes are
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involved in those cell types that are primary targets for HIV infection, CD4+ T cells and
macrophages.

Species-specific variation in the development of a productive infection exists among
primates
Despite the ability of HIV-1 to antagonize human cells in a variety of ways, some species
of non-human primates that become infected with HIV-1 never progress to AIDS, while
other species are never infected after exposure to the virus [34]. Thus, it has been
hypothesized that some non-permissive species of monkeys, primarily Old World
monkeys, have evolved ways to restrict HIV-1 infection by encoding specific cellular
restriction factors that block productive infection [35-38]. This hypothetical restriction
factor to the lentivirus among non-permissive species of monkeys was first called
lentivirus susceptibility factor 1 (Lv1) [39].

The rhesus macaque TRIM5α (RhTRIM5α) protein was the first restriction factor
definitively identified in a monkey to potently restrict HIV-1 infection at a post-entry,
pre-integration stage in the viral life cycle [40].

Subsequent to the discovery of

RhTRIM5α was the discovery of a variety of other species variants of TRIM5α among
the Old World monkeys, such as the owl monkey TRIMCyp protein (a fusion of the
RBCC motif of TRIM5 to cyclophilin A) [41, 42]. Various other restriction factors, such
as Fv1 in mice, as well as APOBEC3G, Bst-2 (Tetherin), a variety of cellular micro
RNAs in humans, and zinc-finger antiviral protein (ZAP) in rats, have been shown to
inhibit retrovirus infections at various other stages in the virus life cycle [43].
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RhTRIM5α as a linking factor for HIV-1 to autophagic degradation
The TRIM (tripartite motif) family of proteins is a large class of zinc-finger proteins,
several of which have been implicated in innate immunity [43-45]. Common to all TRIM
proteins is an RBCC motif containing the RING, B-box 2, and coiled-coil domains (for a
review and explanation of the RhTRIM5α domains, see Fig. 1.6 and G2). RhTRIM5α,
along with several other virus restricting
TRIM proteins, also contains a B30.2(SPRY)
Figure 1.6. RhTRIM5α and domains.
RhTRIM5α is a potent early entry
restriction factor to HIV-1 expressed in
rhesus macaque tissues. The RING domain
of RhTRIM5α has E3 ubiquitin ligase
activity. The B-box 2 domain is required
for HIV restriction. The coiled-coil domain
is the site of RhTRIM5α oligomerization.
The SPRY domain is the site of specific

domain in addition to the RBCC motif.
Studies have shown that the SPRY domain of
RhTRIM5α is critically important for HIV
restriction because it allows for direct

interaction of RhTRIM5α with HIV-1 capsid (CA) protein p24 [46, 47], forming a
complex around the HIV core particle in what is commonly referred to as the
RhTRIM5α-HIV capsid complex (Fig. 1.7). This interaction has been shown to be
essential for significant degradation of the
incoming viral core to occur after fusion with
the cell membrane and release into the
cytoplasm.

However, the exact mechanism

Figure 1.7. RhTRIM5αHIV capsid complex.
Illustration shows HIV's
Fullerene core (made of
self-associating
p24
proteins) surrounded by a
complex of RhTRIM5α
oligomers.

leading to the subsequent degradation of the
viral particle is still unresolved.

The RING domain of this family has been of particular interest in recent years in that it
was found to have E3 ubiquitin ligase activity, which in conjunction with an E2 ubiquitin
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ligase allows the protein to attach ubiquitins to lysine residues within proteins. Several
TRIMs are known to self-ubiquitinate, including the newly discovered TRIM5α from
rhesus macaques [43, 48-50].

However, the function of this self-ubiquitination to

RhTRIM5α restriction of HIV, if any, is still unclear. One of these studies demonstrated
that RhTRIM5α is rapidly turned over in the cell as a result of self-ubiquitination in the
absence of infection [48]. This study went on to hypothesize that self-ubiquitination
targeted RhTRIM5α to the proteasome for degradation.

Several subsequent studies

suggested that self-ubiquitination of RhTRIM5α could be a target for proteasomal
degradation of the entire RhTRIM5α-HIV capsid complex [51-53]. Unfortunately, other
studies were unable to resolve the fact that although proteasome inhibitors were able to
alleviate some of the restrictive capabilities of RhTRIM5α, they were not able to alleviate
all restriction, and, at the same time, were also equally able to alleviate the minimally
restrictive capabilities of human TRIM5α (HuTRIM5α) [54-56]. Furthermore, the DiazGriffero study also showed that altering the rate of poly-ubiquitination of RhTRIM5α
does not affect the rate of degradation of the HIV CA [48]. Thus, based on these
collective works, we hypothesize that the proteasome is not the primary target for CA
degradation, but rather, the autophagosome (referring to the basic physical unit of the
autophagy pathway). We propose that the specific role of RhTRIM5α is to selectively
target HIV-1 viral particles to the autophagosome for the purpose of degradation and
clearance through autophagy. Consistent with our proposal, Chatterji et al suggested that
RhTRIM5α action on the incoming viral particle is entirely proteasome independent and
hypothesized that “proteases other than proteasomal proteases, possibly lysosomal
proteases, are responsible for CA degradation in the vesicular compartment” [56].
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Interestingly, another TRIM has already been implicated in autophagy.

TRIM63

(MuRF1), which regulates skeletal muscle protein, has been shown to do so in an mTORdependent manner [57]. Thus, it is possible that RhTRIM5α might also require mTOR to
degrade HIV, thereby revealing a mechanism for autophagic degradation of HIV.
Finally, another possible mechanism for RhTRIM5α to target HIV to autophagy was
suggested by data showing that TRIM5α associates with hsc70. Hsc70 is the chaperone
protein used in chaperone-mediated autophagy [58]. While this study did not state any
effect of the association of TRIM5α with hsc70, it is possible that this interaction may
mediate yet another alternative method for autophagic capture of incoming HIV core.

TRIM5α may regulate autophagy as part of the innate immune response
Many TRIM proteins have been shown to regulate innate immunity. Among these are:
Pyrin (TRIM20), involved in suppressing inflammation by interacting with the
inflammasome complex; Ro52 (TRIM21), identified as a unique Fc receptor for IgG that
also interacts with IRF8 and is involved in Sjögren's syndrome and systemic lupus
erythematosus, likely as a consequence of its Fc receptor activity; TRIM8, known to
inhibit SOCS1-mediated down-regulation of IFNγ signaling; TRIM25, which promotes
the antiviral response by enhancing RIG-I-mediated signaling (which itself can associate
with autophagy proteins [59]); TRIM27, which down-regulates toll-like receptor (TLR)
signaling by interfering with IKKα/β/γ activity; and last, TRIM56, which has been shown
to regulate double-stranded DNA-mediated type I interferon induction [44, 60, 61].
Many of the regulatory functions of TRIM proteins are mediated by the activity of their
RING domain, especially in the case of TRIM25, which specifically mediates K63
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polyubiquitination of RIG-I to enhance its signaling [62, 63]. It may be that most, if not
all, of these regulatory effects by TRIM proteins might be mediated, in part, through
autophagy.

An interesting aspect of autophagic target recognition is that many proteins that end up in
the autophagosome have K63 type polyubiquitin tags. In fact, some agree that K63
polyubiquitin itself is a tag specifically for autophagosome capture and clearance, much
like the K48 type polyubiquitin tag has been strongly associated with proteasomemediated degradation. The "K63 type" refers to single ubiquitin proteins connected to
each other through a lysine residue at position 63, while the "K48 type" refers to
ubiquitins connected through a lysine at position 48. Depending on the type of lysine
linkage, the tertiary structure of the polyubiquitin varies and is believed to have effects on
the tertiary structure of the protein it tags.

Specifically, studies on the association between K63 type polyubiquitin and autophagy
have shown the following: K63 polyubiquitination of Beclin 1 (mediated by TRAF6,
another RING domain containing protein, involved in the NFκB pathway and previously
known to associate with p62 [64]) can induce autophagy [65], Parkin (yet another RING
domain containing protein, where mutations can lead to Parkinson's disease) induces p62dependent autophagy of mitochondria (mitophagy) through K63 polyubiquitination of
itself and a mitochondrial target(s) [66], and most importantly that autophagic cargo
adaptor p62 itself shows preference for K63 type polyubiquitinated proteins [64, 66-68].
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Thus, several lines of evidence indicate a role for the RING domain of TRIM proteins in
mediating induction of autophagy:

(i) many proteins that end up associated with

autophagy contain K63 type polyubiquitin tags [65-71], (ii) TRIM proteins (TRIM25, 38,
and 21) appear to be capable of mediating K63 type polyubiquitination [62, 63, 72, 73],
(iii) E3 ubiquitin ligases, such as Parkin and TRAF6, can mediate targeting of proteins to
autophagy by K63 polyubiquitination, and (iv) p62, which seems to prefer K63
polyubiquitinated proteins, is already known to associate with another TRIM protein,
TRIM55, during regulation of cardiac myofibril assembly and turnover [74], and likely
also TRIM1 and/or TRIM18 during autophagy of the midbody ring in cytokinesis [75].

Finally, since the Chatterji study showed that proteasome inhibitors were able to increase
the presence of HIV capsid protein (p24) equally in cells expressing either RhTRIM5α or
HuTRIM5α [56], this may indicate that studies with proteasome inhibition have revealed
a second, non-specific mechanism of viral clearance that has previously gone
unrecognized, but requires TRIM5α-induced autophagy. This second mechanism of viral
clearance would be due to a non-specific capture of virus particles by an autophagy that
is in an elevated, non-basal state. This may explain why other studies have reported a
slight, inexplicable, restrictive capability of HuTRIM5α despite the lack of direct
interaction with the viral capsid [40, 45, 76]. Induction of autophagy through TRIM5α
might be accomplished either: directly, with plasmid transfection, leading to the overexpression of the TRIM5α proteins, or indirectly, through the treatment of cells with
IFNβ. The use of type I interferons to stimulate an increase in endogenous TRIM5α
expression has been previously reported [77-79]. These results might reveal a new
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therapeutic target for the prevention of HIV infections, which is that pharmacological
induction of autophagy, at the time of infection, may entirely abrogate the acquisition of
the virus and thus prevent infection with HIV.
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Hypothesis

Based on the published literature described here, I hypothesize that HIV-1 intersects with
the autophagy pathway in a species-specific manner, and that the outcome in
development to AIDS should reflect an ability of HIV-1 to circumvent autophagy and
lead to a productive infection. The following studies investigate this by (i) exploring the
role of autophagy in a primary human cell target for HIV-1, the human macrophage, (ii)
exploring the role of autophagy in HIV infection in the presence of a non-human primate
restriction factor, RhTRIM5α, and (iii) exploring a newly revealed ability for this
restriction factor to regulate autophagy.

Dissertation Summary

Chapter 2: Autophagy pathway intersects with HIV-1 biosynthesis and regulates
viral yields in macrophages
In this chapter, we explore the interactions between autophagy and the HIV-1 life cycle
in the human macrophage. We reveal a mechanism by which autophagic elimination of
HIV-1 is impaired and uncover a surprising contribution of the autophagy pathway to
HIV-1 biosynthesis.

Furthermore, we identify the factor responsible for these

opportunistic effects on autophagy as the HIV-1 protein Nef and show that the actions of
Nef require its diacidic motif 174DD175.

Chapter 3: Autophagy-mediated restriction of HIV-1 by RhTRIM5α
In this chapter, we explore a requirement for autophagy in the degradation, and
subsequent restriction, of HIV-1 by the rhesus macaque restriction factor, rhesus TRIM5α
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(RhTRIM5α). Here we show that degradation of the incoming HIV-1 viral capsid (CA)
by RhTRIM5α depends on an interaction with the autophagic machinery through p62 and
that degradation of the viral CA requires an intact autophagy, which can be inhibited with
siRNA, bafilomycin A1, or e64d and pepstatin A treatment.

Chapter 4: TRIM5α is an innate immunity regulator inducing autophagy
In this chapter, we uncover a surprising ability of the TRIM5α of either species to
regulate autophagy. Specifically, we show that both species variants are capable of
inducing autophagy and explore a possible mechanism by which autophagy could be
controlled by TRIM5α. We find that interaction with the autophagic machinery through
p62 is not unique to RhTRIM5α, as human TRIM5α (HuTRIM5α) also interacts with
p62. Finally, we propose a mechanism by which either TRIM5α can induce autophagy,
and present the hypothesis that regulation of autophagy by TRIM5α represents a unique
form of autophagy-mediated innate immunity regulation.

Chapter 5: Discussion and future implications
Here we summarize our findings from the above studies and discuss future implications
of our research to the treatment of HIV-1 infection. We discuss new literature published
since these studies began that support our findings and shed new light on our
understanding of the mechanisms revealed by each study. Finally, we discuss the future
directions to the research and results uncovered here.
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CHAPTER 2

AUTOPHAGY PATHWAY INTERSECTS WITH HIV-1 BIOSYNTHESIS AND
REGULATES VIRAL YIELDS IN MACROPHAGES
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Abstract

Autophagy is a cytoplasmic degradative pathway that can participate in biosynthetic
processes, as in the yeast Cvt pathway, but is more commonly known for its functions in
removing damaged or surplus organelles and macromolecular complexes. Here, we find
that autophagy intersects with human immunodeficiency virus (HIV) biogenesis,
mirroring the above dichotomy. Early, nondegradative stages of autophagy promoted
HIV yields. HIV Gag-derived proteins colocalized and interacted with the autophagy
factor LC3, and autophagy promoted productive Gag processing. Nevertheless, when
autophagy progressed through maturation stages, HIV was degraded. This, however,
does not occur, as the HIV protein Nef acts as an antiautophagic maturation factor
through interactions with the autophagy regulatory factor Beclin 1, thus protecting HIV
from degradation. The dual interaction of HIV with the autophagy pathway enhances
viral yields by using the early stages while inhibiting the late stages of autophagy. The
role of Nef in the latter process enhances yields of infectious HIV and may be of
significance for progression to clinical AIDS.
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Introduction

Autophagy is a general homeostatic process in eukaryotic cells whereby protions of the
cytoplasm, containing cytosol or organelles, are sequestered into double membranebound autophagic vacuoles for fusion with lysosomal organelles and subsequent
degradation of the captured contents in the resulting autolysosomes [80, 81].

A

functional core autophagy pathway and associated processes are important for cell
survival under starvation or growth factor withdrawal conditions, programmed cell death,
elimination of aggregated proteins, and removal of surplus or damaged organelles [82,
83]. Autophagy is regulated by signaling pathways centered around the Ser/Thr protein
kinase Tor (target of rapamycin) and phosphatidylinositol 3-kinases (PI3Ks), both type I
(inhibitory to autophagy) and type III (essential for execution of autophagy). The type III
PI3K hVPS34 acts in a complex with Beclin 1 (yeast Atg6), a factor endowing hVPS34
with its role in autophagy [8]. A detailed picture on these and other autophagy proteins
(Atg) in mammalian cells is emerging, with the core pathway resembling that in yeast
[80-82].

Autophagosome biogenesis and wrapping around autophagic targets is facilitated by the
two specialized protein conjugation systems: the Atg5-12/16 complex stimulates a second
conjugation system, whereby LC3 (Atg8) undergoes conversion from its free C-terminus
state (LC3-I) to its C-terminally lipidated form (LC3-II) covalently modified by
phosphatidylethanolamine. The lipidated LC3-II localizes to the membrane of a growing
phagophore.

Once a phagophore closes, this results in the formation of a double

membrane-delimited autophagosome that typically matures into an autolysosome through
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fusion with multivesicular body (MVB) compartments [84] and other lysosomal
organelles [80]. Most cells undergo baseline autophagy to remove protein aggregates and
spuriously damaged mitochondria or other organelles, or to adjust the cellular biomass
[83]. With a broad range of targets, ranging from protein complexes to whole organelles,
autophagy is a process affecting a multitude of health and disease states; has been
implicated in neurodegeneration, cancer, and aging [83]; and has emerged as an
important player in inflammatory and infectious diseases [5, 85].

Autophagy is now well recognized as an innate and adaptive immunity mechanism [85,
86]. Pharmacologically, physiologically, or immunologically induced autophagy can act
as a powerful antimicrobial defense [5, 85, 87-93]. Autophagy is under the control of
immune receptors and cytokine signaling [85, 86], and is stimulated upon microbial
recognition by innate immunity pattern recognition receptors [94-97] or activation with
Th1 cytokines [98]. However, certain pathogens can harness this process to assist their
own propagation [5, 18, 19, 91]. Interestingly, a recent large scale siRNA screen of host
cell factors required for human immunodeficiency (HIV) type 1 (HIV-1) replication has
identified several Atg factors among >250 HIV dependency host genes [33]. Thus far, no
in-depth functional links between Atg proteins or processes and HIV have been
established.

Here, we tested mechanistically whether and how autophagy affects HIV yields during de
novo virion generation. We found that the Atg proteins LC3 and Beclin 1 (Atg6) are
found in complexes with the HIV proteins Gag and Nef, respectively.
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The latter

interaction provides the basis for Nef function in control of autophagy. The Nef protein
of HIV-1 and simian immunodeficiency virus (SIV) is required for efficient viral
replication and acquired immune deficiency syndrome (AIDS) pathogenicity in HIV-1infected humans or SIV-infected macaques [99-101]. The methods by which Nef protein
acts as a pathogenic factor in vivo are not fully understood, but involve several
mechanisms [102-105]. Recent findings suggest that the inability of lentivirus Nef to
suppress CD4+ T cell activation correlates with viral pathogenesis [106, 107]. Our
findings presented here uncover an additional, previously unappreciated Nef action in
control of autophagy. Nef functions in preventing destruction of HIV from autophagy in
its role of a cell autonomous antimicrobial defense.

Results

Basal autophagy augments HIV yields in macrophages
Basal autophagy is operational in all cell types, particularly in mononuclear phagocytic
and dendritic cells [108]. To test whether basal autophagy can affect HIV yields, we
pharmacologically inhibited autophagy in primary human macrophages differentiated
from peripheral blood monocytes and infected with the macrophage-tropic HIV strain
SF162, and determined yields of the infectious virus released from the macrophages. The
macrophages treated with 3-methyl adenine (3MA), a conventional inhibitor of
autophagy, yielded three-fold fewer infectious virions compared with the untreated
control (Fig. 2.1A). The magnitude of this effect could be increased with higher inhibitor
concentrations, but we used mild pharmacological and other treatments in these and
subsequent experiments to avoid nonspecific effects. The autophagy requirement for
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Figure 2.1. Autophagy is required for optimal HIV yields in macrophages. (A) Pharmacological
blockage of autophagy inhibits release of infectious virions. Human peripheral blood MDM were
infected with SF162 HIV-1 for 10 d, then washed and incubated with control media or 3MA for 4.5 h.
Culture supernatants containing HIV particles were used for a MAGI infectivity assay as described in
Materials and methods. (B) Relative viral release was calculated as a ratio of extracellular-tointracellular Gag-derived core antigen capsid protein CA (p24) and normalized to the control. (C)
Western blot showing siRNA knockdown of Beclin 1, 7 d after transfection in MDM. (D) Human
MDM were transfected with siRNA to Beclin 1 and infected with SF162 HIV-1 for 7 d, then p24
yields were quantified. (E) Western blots showing siRNA knockdown of Beclin 1 and Atg7 48 h
after transfection in U937 cells. (F) Knockdown of autophagy regulators Atg7 and Beclin 1 inhibits
basal viral yields released from macrophages. U937 cells were cotransfected with Beclin 1 or Atg7
siRNA and pMSMBA (a clone of NL4-3). Data indicate means; error bars indicate ±SEM (n ≥ 3). *,
P < 0.05; **, P < 0.01; †, P > 0.05 (analysis of variance [ANOVA]). (G) U937 cells were knocked
down for Beclin 1 expression and infected with VSV-G-pseudotyped HIV. Cell lysates were
prepared for Gag processing analysis. *, P < 0.05, paired t test.

optimal HIV yields also assessed by determining extracellular release of the HIV capsid
protein Gag p24 [109]. The p24 released from live virus-infected primary macrophages
was reduced in cells subjected to inhibition by 3MA (Fig. 2.1B).

Because

pharmacological inhibitors such as 3MA may not affect only the autophagic pathway, we
ascertained a role of the bona fide autophagy pathway by knocking down Beclin1 (Atg6)
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in primary macrophages (Fig. 2.1C and D) and in macrophages differentiated from
monocytic U937 cells (Fig. 2.1E and F). Knockdown of Beclin 1 diminished p24 yields
in both primary monocyte- and U937-derived macrophages (Fig. 2.1D and F).

A

knockdown of another essential autophagy factor, Atg7, resulted in a similar effect on
p24 yields (Fig. 2.1F); Atg7 and Beclin 1 knockdowns affected autophagy in U937 cells,
as determined by GFP-LC3 puncta/cell counts (Fig. A1).

We next examined the

intracellular Gag processing by monitoring Gag-derived p24 band intensity in
immunoblots of cell extracts. When U937 cells knocked down for Beclin 1 were infected
with vesicular stomatitis virus G (VSV-G)-pseudotyped NL4-2 HIV-1, cellular p24 levels
were reduced compared with controls (Fig. 2.1G). Collectively, these results indicate that
basal autophagy promotes optimal Gag processing and yields of HIV in macrophages.

HIV and HIV Gag-derived proteins colocalize with the autophagy marker LC3
To test whether and how the autophagy pathway intersects with HIV, we examined the
relative distribution of HIV virions and Atg proteins. In macrophages, HIV virions are
found in membranous domains [110-115] recently shown to be contiguous with plasma
membrane [114, 116, 117], which facilitates colocalization studies.

The Gag-p17-

specific antibody showed colocalization of the budded virus with autophagy marker LC3
(Atg8; Fig. 2.2A). By ultrasctructural analysis, HIV virions were observed in these
compartments (Fig. 2.2B), which, based on presence of clathrin-coated pits (Fig. 2.2B,
asterisk; Fig. A1C), were consistent with the previously reported plasma membrane
connections [114]. These morphologically identified compartments also labeled for LC3
(Fig. 2.2C) and p24 (Fig. A1D). A dual labeling procedure was not practicable, as LC3
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Figure 2.2. Autophagy protein LC3 colocalizes, copurifies, and coprecipitates with HIV Gag.
(A) MDM were infected with VSV-G-pseudotyped HIV and immunostained for Gag-p17 and LC3.
Arrows, a peripheral structure as an example of Gag-p17 and LC3 overlap. (B) Ultrastructural
analysis of HIV virions in macrophages infected with HIV. U937 cells were infected with VSV-Gpseudotyped HIV.
(inset) Enlarged region boxed in the electron micrograph. White arrow,
membrane; black arrow, HIV virion; asterisk, HIV virions in a membranous compartment with a
clathrin-coated pit consistent with plasma membrane origin. An enlarged image of this profile is
shown in Fig. A1C. (C) HIV-containing compartments are positive for LC3. Immunoelectron
microscopy showing gold particles (enhanced gold particles appear globular, oval, and acicular) of
LC3 in HIV-containing compartments. Arrow: virion and LC3 gold particle. See Fig. A1D for p24
immunoelectron microscopy analysis. (D) HIV Gag precursor and Gag-derived proteins cofractionate
with LC3 and the tetraspanin CD9. Subcellular organelle fractionation via isopycnic sucrose gradient
separation was performed with lysates from HIV- infected cells (see Materials and methods). 12
fractions starting from the top were immunoblotted for the indicated proteins and organellar markers.
The box with the broken line indicates peak band intensity fraction for LC3-II, Gag, and Gag-derived
polypeptides, and CD9. (E) HIV Gag coimmunoprecipitates with LC3. U937 cells were infected
with HIV and lysates immunoprecipitates for LC3. Immunoblotting with p24 and LC3 antibodies
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was performed on lysate and immunoprecipitate samples. The p24 antibody recognizes all three Gag
proteins, as shown in the input. Note that only the precursor Gag-p55 comes down in
immunoprecipitates with LC3 (n = 3).

enhanced immunogold labeling resulted in globular, oval, and

acicular shapes, and

precluded clear distinction.

Biochemical analysis of HIV Gag-derived proteins shows copurification and
interactions with the autophagic protein LC3
To determine at the biochemical level whether HIV intersects with the autophagy
pathway, we subjected HIV-infected marcophages to subcellular fractionation by
isopycnic centrifugation in sucrose gradients.

Fig. 2.2D shows that membranes

containing HIV Gag polypeptides p24 and p17 cofractionated (note the coinciding peaks
framed in Fig. 2.2D) with the autophagic protein LC3. These membranes were enriched
for the lipidated for of LC3, LC3-II, normally generated during engagement in an
autophagic conjugation cascade driving autophagy initiation and elongation [118], and
the recently recognized plasma membrane-associated autophagic events in macrophages
[95]. As expected, LC3-I, the soluble cytosolic form of LC3, was not found on these
membranes, although it was detectable in whole cell lysates (Fig. A2A). The LC3-IIpositive membranes enriched for Gag p55, Gag processing intermediate gp41, and Gag
products p24 and p17 did not copurify with the ER marker calnexin, but did cofractionate
with CD9, a tetraspanin previously reported to colocalize with HIV virions in monocytederived macrophages (MDM; Fig. 2.2D; [114]).

We

next

tested

whether

HIV

coimmunoprecipitation experiments.

Gag

interacted

with

autophagy

proteins

in

Fig. 2.2E shows that LC3 is found in protein
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complexes with the HIV Gag. These findings reinforce the subcellular fractionation
experiments (Fig. 2.2D), are in keeping with morphological analyses (Fig. 2.2A-C), and
demonstrate that HIV components and virions intersect with the autophagic pathway with
the functional consequence of augmenting Gag processing (Fig. 2.1G) and HIV yields
(Fig. 2.1A-F).

Pharmacological induction of autophagy enhances HIV yields
We next reasoned that although the basal autophagy is required for optimal HIV yields,
physiologically, pharmacologically, and immunologically induced autophagy might
affect HIV yields differently, i.e., by degrading HIV components en route to or at viral
assembly sites. Significantly, induction of autophagy occurs during HIV infection of
macrophages, as described previously [97]. Infection of primary human peripheral blood
MDM with HIV-1 strain SF162 virus increased LC3-II levels at 10 d after infection (Fig.
2.3A and B), which coincided with the expected [119] peak HIV production in primary
peripheral blood mononuclear cells.

To test the effects of induced autophagy, macrophages were treated with the conventional
inducer of autophagy rapamycin, and extracellular HIV yields were determined. Primary
macrophages treated with rapamycin yielded higher p24 levels than untreated control
when infected with the live virus or transfected with a virus molecular clone (Fig. 2.3C
and D). The increase in p24 was not caused by a nonspecific leakage of cytoplasmic
contents, as the cytosolic enzyme lactate dehydrogenase levels found in the medium were
not altered by rapamycin treatment (Fig. 2.3E). Similar results were obtained when two
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Figure 2.3. Induction of autophagy enhances HIV yields. (A) Human peripheral blood MDM were
infected with SF162 HIV-1 for 3 or 10 d, and lysates were immunoblotted for LC3 (one of two equal
experiments shown). (B) Quantification: LC3-II band intensity relative to actin. Representative data
from one of two independent experiments. (C and D) Induction of autophagy promotes viral yields
from MDM. (C) MDM were infected with SF162 HIV for 10 d, then washed and incubated with
DMSO or 50 μg/ml rapamycin for 4 h. (D) MDM were transfected with a pMSMBA HIV clone for
48 h, then washed and incubated with DMSO or 50 μg/ml rapamycin for 4 h. (D) MDM were
transfected with a pMSMBA HIV clone for 48 h, then washed and incubated with DMSO or 50 μg/ml
rapamycin for 4 h. Core antigen capsid protein (p24) was measured as in Fig. 2.1. (E) Assessment of
nonspecific cytosolic release. Extracellular lactate dehydrogenase (LDH) release assay was
performed with a kit from Promega according to manufacturer's instructions using lysates and media
from cells treated with DMSO or rapamycin. Relative LDH was calculated as the ratio between
extracellular and total LDH, released from MDM from two different donors. (F) Induction of
autophagy increases p24 yields in human monocytic cell lines. THP-1 and U937 cells differentiated
into macrophages were transfected with pMSMBA for 48 h, then washed and incubated with DMSO
or rapamycin for 4 h. (G) Induction of autophagy increases release of VLPs in human macrophages.
U937 cells were infected with VSV-G-pseudotyped pMSMBA-derived virus for 48 h, then washed
and treated for 5 h with rapamycin or DMSO alone. VLPs were isolated on a 20% sucrose cushion,
and lysates and VLP were immunoblotted for Gag and p24, respectively. (H) U937 cells were co
transfected with siRNA and pMSMBA for 48 h, then washed and incubated with DMSO alone or
50μg/ml rapamycin for 4 h. (I) HeLa and H9 cells were transfected with pMSMBA for 48 h, then
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washed and incubated with DMSO or rapamycin for 4 h, and relative viral release (p24) was
determined. (J) H9 cells (a T cell line) were infected with T cell tropic HIVLAI for 4 d and washed;
relative viral release was found by determining the ratios of extracellular versus intracellular reverse
transcription levels. Data indicate means; error bars indicate ±SEM (n ≥ 3). *, P < 0.05; **, P < 0.01;
†, P > 0.05 (ANOVA).

monocytic cell lines, THP-1 and U937, differentiated into macrophages were tested (Fig.
2.3F).

Immunoblot analyses of cell-associated viral proteins and p24 in virus-like

particles (VLP) in culture medium indicated that the increased p24 yield in macrophages
treated with rapamycin was associated with VLP released from macrophages (Fig. 2.3G).
The autophagy machinery in these experiments was intact, as indicated by response to
rapamycin both with LC3-I-to-LC3-II conversion and LC3 puncta formation (Fig. A2BD), and responsiveness of the effects to inhibition with the conventional autophagy
inhibitor 3MA (Fig. A2C and D). The enhancement effect of rapamycin on p24 release
was counteracted by knocking down the key regulator of autophagy Atg7 (Fig. 2.3H).
Because Atg7 is a key autophagy factor, this indicates that the rapamycin effects on p24
are autophagy dependent. Thus, pharmacological induction of autophagy, in contrast to
our predictions and previous findings of inhibitory effects on viral replication of
rapamycin in low concentrations [120, 121], did not diminish but instead enhanced yields
of the virus released from macrophages. The effects of autophagy induction appeared to
be specific for macrophages, as we did not observe enhancement using rapamycin in
HeLa or H9 T cell lines transfected with an HIV molecular clone (Fig. 2.3I) and H9 T
cells infected with the CXCR4 coreceptor using (X4, T cell tropic) virus HIVLAI (Fig.
2.3J).

HIV protein Nef is required for enhanced HIV yields in response to autophagy
induction
34

Given the observation that induced autophagy did not harm the virus, but further
augmented its yields, we wondered whether the virus, in addition to using basal
autophagy to increase its yields, also protected against induced autophagy, which can act
as an antimicrobial cell-autonomous defense [82, 87-89, 91-93].
whether specific HIV-1 proteins affected autophagic machinery.

We investigated
A release of HIV

deleted for Nef was not stimulated by rapamycin in cells transfected with pNL4-3ΔNef,
as shown in Fig. 2.4A, where the data were normalized to represent fold change in
relative p24 release. These data show that rapamycin has no additional effect on HIV
yields when the virus lacks Nef. The absolute levels of both the released p24 and cellassociated p24 were proportionately reduced with HIVΔNef treated with rapamycin (Fig.
2.4A, inset). As a consequence, the ratios remained the same (Fig. 2.4A, main graph),
although the absolute levels of p24 (both cellular and released) were diminished (Fig.
2.4A, inset).

In contrast to Nef deletion, HIV deleted for Vpu still responded to

rapamycin stimulation with increased p24 levels (Fig. 2.4C). Furthermore, ΔNef virus,
although showing reduced relative release of the viral p24 (Fig. 2.4C) and cellular p24
levels (Fig. 2.4D), showed no further change in yields, release, or cellular p24 when
autophagy was inhibited by 3MA (Fig. 2.4E, left two panels) or suppressed by Beclin 1
knockdown (Fig. 2.4E, right two panels), indicating that Nef is critical for the detectable
effects of autophagy on HIV.

HIV causes Nef-dependent accumulation of early autophagic markers
We next examined HIV effects on the execution stages of autophagy. The gold standard
for assessment of the early execution phases of autophagy (initiation and elongation) is
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Figure 2.4. Nef is required for yield-enhancing effects of autophagy on HIV. (A) U937 cells
were transfected with pGFP-NL43ΔNef (HIVΔNef) for 48 h and incubated with DMSO or 50 μg/ml
rapamycin. (inset) Absolute values of p24 concentrations in cells (open bars) and released into the
medium (shaded bars). Note that absolute levels of ΔNef virus are inhibitable by rapamycin but that
the ratios of released versus cell-associated virus remain the same, as reflected in the main graph. (B)
U937 cells were transfected with pMSMBA-Vpu-null (HIVΔVpu) and tested as in A for rapamycin
effects. (C) U937 cells were infected with 100 ng/ml each of VSV-G-pseudotyped HIV or HIVΔNef
for 48 h, and p24 yields were quantified. (D) Absolute levels of cell-associated, released, and total
p24 from samples in B. (E) Absence of basal autophagy inhibition effects on HIVΔNef yields. For
experiments with 3MA, U937 cells were infected with NL4-3ΔNef for 48 h, then washed and treated
for 4 h. Cells in experiments with Beclin 1 knockdowns were first transfected with siRNA, infected
24 h later, and harvested 48 h after infection. CTR, control. (F and G) Nef increases LC3-II
(lipidated form). U937 cells were infected with VSV-G-pseudotyped pMSMBA-derived virus (HIV)
or HIVΔNef for 3 d and immunoblotted for LC3. (E) Immunoblot. (F) Quantification (ratio of LC3II to GAPDH band intensities). (H) U937 macrophages were cotransfected with GFP-LC3 and either
DsRed2 or Nef-DsRed2 for 24 h. GFP-LC3 puncta were quantified in three independent experiments.
(I) Quantification of LC3 puncta (≥ 1μm) per cell. Data indicate means; error bars indicate ±SEM (n
≥ 3). *, P < 0.05; **, P < 0.01; †, P > 0.05 (ANOVA).

based on monitoring biochemical and morphological changes that the autophagy protein
LC3 undergoes [118].

During the stages when autophagic isolation membranes

(phagophores) begin to form and nascent autophagosomes elongate until they are
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completed by closure, LC3 converts from the nonlipidated cytosolic species (LC3-I) to a
predominantly membrane-associated form (LC3-II) covalently modified at the C
terminus by phosphatidylethanolamine. During maturation stags, LC3-II is consumed as
a portion of it gets degraded in the autolysosomes. The level of LC3 lipidation is
monitored by immunoblotting, and detected as a conversion from the unmodified LC3-I
band to the lipidated LC3-II form, which shows increased electrophoretic mobility [118,
122]. Complete HIV, but not HIV deleted for Nef, increased levels of lipidated LC3, as
reflected in the increase of LC3-II band on Western blots (Fig. 2.4F), and LC3-II/loading
control ratios [122] using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the
loading reference (Fig. 2.4G). We next used another standard assay of autophagy, based
on fluorescence microscopy detection of LC3 on autophagic membranes as punctate
GFP-LC3 (LC3-II) vis-à-vis diffuse cytosolic GFP-LC3 (LC3-I; [118]). U937 cells were
transfected with the previously well characterized expression clone of Nef-DsRed2,
thoroughly documented in cell biological studies to fully correspond both in distribution
and function to the untagged Nef [123]. Transfection of U937 cells with Nef-DsRed2
resulted in an increased abundance of GFP-LC3 puncta versus control DsRed2transfected cells (Fig. 2.4H and I; and Fig. A2E).

Thus, Nef was responsible for

accumulation of the early autophagic markers, the lipidated LC3-II form and LC3 puncta.

Nef inhibits autophagic maturation
The observed increase in early autophagic markers associated with Nef action is
consistent with: (a) induction of autophagy or (b) a blockage of the maturation stages of
autophagy. We first examined whether Nef affected the maturation (degradative) stages
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of the autophagic pathway. This was performed by testing Nef effects on the marquee
autophagic degradative function: proteolysis of long-lived, stable proteins that are
normally turned over by autophagy.

We tested whether Nef affected autophagic

proteolysis using the published assay for stable protein autophagic proteolysis in
macrophages, optimized and functional only in the mouse macrophage cell line
RAW264.7 [124]. Transfection with Nef-DsRed2 did not induce autophagic proteolysis
(Fig. A3A). Instead, Nef-DsRed2 inhibited autophagic protein degradation induced by
starvation, a gold standard for assessment of autophagy function (Fig. A3A). Thus, Nef
inhibits terminal, degradative stages of autophagy.

The role of Nef in inhibiting degradative stages of autophagy was further examined in
human cells using the RFP-GFP-LC3 probe, a specialized tool for investigation of the
autophagic flux, i.e., the maturation of autophagic organelles into degradative
autolysosomal compartments [125]. Based on the sensitivity of GFP fluorescence to
acidic pH and insensitivity of RFP fluorescence to low pH, it is possible to differentiate
early, nonacidified autophagosomes (red+green+; yellow in merged images) from
acidified, degradative autophagic organelles (red+green-; red in merged images; [125]).
In cells infected with Nef+ HIV, there was a pronounced accumulation of red+green+
(yellow) puncta, compared with uninfected cells or cells infected with ΔNef HIV (Fig.
2.5A-C). This is in keeping with the conclusion that Nef blocks maturation of early
autophagic organelles into acidified, degradative autolysosomes. Of the Nef-dependent
red+green+ puncta, 85% were negative for the lysosomal protein Lamp2 (Fig. 2.5D). All
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Figure 2.5. Nef inhibits autophagic maturation. (A) Nef blocks maturation of early autophagic
organelles into autolysosomes. 293T cells were infected with VSV-G-pseudotyped HIV or HIVΔNef
and transfected with mRFP-GFP-LC3 for 48 h, then immunostained for Gag and analyzed by
confocal microscopy. Based on differential pH sensitivity of RFP and GFP, the mRFP-GFP-LC3
probe differentiates between early, nonacidified autophagosomes (red+green+; yellow in merged
images) from acidified, degradative autolysosomes (red+green-; red in merged images0. (B and C)
Quantification of (red+green+) R+G+ and R+G- puncta per cell, respectively. (D) Analysis of Lamp2
association with RFP-GFP-LC3 profiles in HIV-infected 293T cells (HIV infection of >90%
determined by staining with antibody to Gag). L+, percentage of Lamp2-positive profiles; L-,
percentage of Lamp2-negative profiles. Data are from 42 cells from three slides. (E) LC3-II levels in
Nef-transfected cells in the presence or absence of bafilomycin A1. 293T cells were transfected with
GFP alone or Nef-GFP for 48 h. Cells were then incubated with or without bafilomycin A1 (Baf A1
or Baf) for 4 h and immunoblotted for LC3 and GAPDH. (E, bottom) Quantification: LC3/GAPDH
ratios, representative of one of two experiments. (F) Inhibition of autophagic flux/maturation protects
Nef-null virus from degradation. U937 cells were infected with VSV-G-pseudotyped HIVΔNef for
72 h, then washed and treated with rapamycin or rapamycin plus bafilomycin A1 (100 nM) for 5 h.
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VLP and cell lysates were subjected to immunoblot analysis. (F, right) Quantification of cellular p24
(n = 3). Data indicate means; error bars indicate ±SEM. *, P < 0.05; **, P < 0.01; †, P ≥ 0.05
(ANOVA).

red+green- puncta (representing 31% of the total mRFP-GFP-LC3 puncta) were Lamp2
positive (Fig. 2.5D). Expression of Nef-GFP resulted in an increase of LC3-II (Fig.
2.5E). This was not or only slightly enhanced in the presence of bafilomycin A1 (Fig.
2.5E, graph), an inhibitor of autophagosomal/autolysosomal acidification used to
differentiate between effects on autophagy induction versus maturation [122], which
suggests that the bulk of Nef effects on autophagy were based on blocking autophagic
flux.

Nef blocks autophagic degradation of HIV
We next tested whether Nef blocks HIV-specific autophagic degradation by monitoring
the yields of HIV p24. U937 cells were infected with VSV-G-pseudotyped Nef-null HIV
and treated with rapamycin. This led to a marked decrease in intracellular p24 levels and
in lower p24 levels in VLP preparations (Fig. 2.5F). The decrease in p24 was abrogated
with bafilomycin A1, which blocks autophagic degradation (Fig. 2.5F). Similar results
were observed with cellular p24 levels (Fig. 2.5F). These findings strongly indicate that
Nef inhibits autophagic degradation of HIV biosynthetic intermediates or virions, and
that this in turn enhances HIV yields.

HIV Nef colocalizes with autophagy regulators and is found in Beclin 1 protein
complexes
We next investigated intracellular distribution of Nef in relationship to autophagy
regulators. Nef did not colocalize with mTOR (Fig. A3B), so it is unlikely that it affects
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Tor directly. Nef showed a partial colocalization with 2xFYVE-GFP (Fig. A3C), a probe
binding to membranes containing phosphatidylinositol 3-phosphate (PI3P), the enzymatic
product of type III PI3K hVPS34 that plays a critical role in autophagy when complexed
with Beclin 1 [8, 126-128]. Nef showed colocalization with autophagy factors Atg7 and
Atg12 (Fig. A3D and E), and colocalized (Figs. 2.6A and A3F) with the autophagic
protein Beclin 1, which is the central regulator of autophagy at multiple stages [8, 129].
Immunoprecipitation of Beclin 1 in extracts from cells transfected with Nef-GFP resulted
in the presence of Nef-GFP in the precipitated protein complexes (Fig. 2.6B, top left).
GFP was absent from the control samples when Beclin 1 was immunoprecipitated from
cells transfected with GFP alone (Fig. 2.6B, top right). A converse experiment using
immunoprecipitation of GFP revealed the presence of Beclin 1 in immune complexes in
cells transfected with Nef-GFP (Fig. 2.6B, bottom left) but not in extracts from cells
transfected with GFP alone (Fig. 2.6B, bottom right). In a different configuration, using
cells transfected with C-terminally myc epitope-tagged Nef, Beclin 1 was found in
immunoprecipitates

generated

with

myc

antibodies

(Fig.

2.6C).

In

all

immunoprecipitation experiments, IgG control showed negative results for the specific
proteins analyzed (Fig. 2.6). The blots shown with the IgG control were developed until
very faint band (representing background in any type of immunoprecipitation
experiments) was revealed when possible; shorter development times left IgG controls
completely blank, whereas the specifically coimmunoprecipitated band were still
detected. Importantly, HIV Nef also coimmunoprecipitated with Beclin 1 in extracts
from cells infected with HIV virus (Fig. 2.6D), demonstrating that Nef-Beclin 1
complexes form during viral infection. Thus, Beclin 1 and Nef colocalize (Fig. 2.6A) and
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Figure 2.6. Nef is in protein complexes with autophagy regulator Beclin 1. (A) Macrophages
were transfected with Nef-GFP and immunostained for Beclin 1. Arrows, perinuclear profiles
exemplifying Nef and Beclin 1 colocalization. (inset) Peripheral colocalization. (B) 293T cells were
transfected with Nef-GFP or GFP alone for 48 h. Lysates were immunoprecipitated either with
Beclin 1 antibody and immunoblotted with Nef antibody (top) or with GFP and immunoblotted for
Beclin 1 (bottom). Specific protein levels in cell lysates (input) and immunoprecipitations with IgG
controls are shown. (C) Coimmunoprecipitation of Beclin 1 with Nef-Myc. 293T cells were
transfected with Nef-Myc for 48 h. then cells were lysed and immunoprecipitation was performed
using monoclonal Myc antibody or IgG control. The blost shown represent one of four independent
experiments. (D) U937 cells were infected for 48 h with VSV-G-pseudotyped HIV. Cells were lysed
and immunoprecipitated with Beclin 1-specific antibody or control IgG. Western blots of
immunoprecipitated material were probed with Nef antibody. (E and F) 293T cells were
cotransfected with Nef-GFP or GFP and Flag-hVPS34 for 48 h. Cells were fractionated into
membranes (M) and cytosol (C) and immunoblotted with anti-Flag and Beclin 1 antibodies. (E)
Immunoblots. (F) Quantification (ratios of membrane-associated hVPS34 to cytosolic hVPS34. Data
indicated means; error bars indicate ±SEM. *, P < 0.05 (n = 3).

are present in a shared protein complex (Fig. 2.6B-D), associating directly or indirectly
via an intermediate partner. Furthermore, Nef affected hVPS34 distribution (Fig. 2.6E
and F), as a consequence of its association with Beclin 1, resulting in an increased
presence of hVPS34 on membranes.
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Mutational analysis of HIV Nef-Beclin 1 interactions and Nef effects on autophagy
We next used a panel of Nef mutants to test whether any of the known motifs were
necessary for Nef interactions with Beclin 1 and Nef effects on autophagy (Fig. 2.7A and
A3G). In an identical coimmunoprecipitation approach as in Fig. 2.6, the previously
characterized Nef mutant construct [130] with changes in the diacidic motif (174DD175 →
174

AA175), responsible for interactions with the V1 domain of vacuolar H+ ATPase and

required for CD4 down-regulation [105], lost the capacity to coimmunoprecipitate Beclin
1 (Fig. 2.7A). In contrast, the mutation

154

EE155 →

154

QQ155, in another region of Nef,

i.e., the diacidic motif required for β-COP interactions [29, 105], did not significantly
diminish the capacity of Nef to coimmunoprecipitate with Beclin 1 (Fig. 2.7A). Another
mutation 2G → 2A, abrogating the ability of Nef to be N-terminally myristoylated, a
posttranslational modification assisting Nef in membrane localization and required for
many Nef functions [105], did not affect the capacity of Nef to coimmunoprecipitate with
Beclin 1 (Fig. 2.7A).

Myristoylation of Nef is often considered a sine qua non

posttranslational modification required for nearly all previously known functions of Nef
[105], with the exception of Hck activation by Nef [131], and thus it may appear
surprising that this did not nullify Nef's action in our assays. However, it has been shown
[132] that membrane association of NefG2A is not fully abrogated despite the loss of
myristoylation, but that instead it may be shifted from plasma membrane to
endomembranes, which is compatible with the action of Nef within the autophagic
pathway.
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Figure 2.7. Nef 174DD175 motif is required for interaction with Beclin 1 and inhibition of
autophagic maturation. (A) 293T cells were transfected with the wild-type HIV-1 Nef fusion with
GFP or the indicated mutants: G2ANefGFP, 154EE-GG155NefGFP, and 174DD-AA175NefGFP for 48 h.
Beclin 1 immunoprecipitates were analyzed by immunoblotting. (B and C) 293T cells were
tranfected with the indicated constructs and immunoblotted for LC3. (B) Immunoblot. (C)
Quantification (ratio of LC3-II to GAPDH band intensities). Data indicate means; error bars
indicated ±SEM. *, P < 0.01; †, P ≥ 0.05 (ANOVA; n = 3).

The same set of Nef mutants was tested for their capacity to increase the LC3-II form
(Fig. 2.7B and C). The 174DD175 → 174AA175 mutant was again the only Nef variant tested
that resulted in reduced increase in the autophagic marker LC3-II. Identical results were
obtained when expression levels of Nef mutants were adjusted (Fig. A3G). Thus, based
on interaction assays with Beclin 1, and functional analysis with LC3-I-to-LC3-II
conversion, the diacidic motif at the positions 174 and 175 of Nef is critical for the ability
of Nef to control autophagic flux.

Discussion

This study shows that autophagy factors interact with HIV components, that basal
autophagy augments Gag processing and HIV yields in macrophages, and that HIV
inhibits degradative stages of autophagy. Our data show that HIV proteins Gag and Nef
interact with two different autophagy factors and that this controls the autophagic
pathway in infected cells with the net result of enhancing HIV yields. The rationale for
our study was based on a growing recognition of autophagy as an antimicrobial cell44

autonomous defense mechanism endowing eukaryotic cells with the ability to eliminate
invading

microbes

[5].

However,

we

found

that

autophagy,

even

when

pharmacologically induced, could not decrease HIV yields in macrophages, and that
instead it enhanced HIV production. HIV protein Nef binds to the protein complexes
containing the mammalian autophagy protein Beclin 1. Nef inhibits the degradative
stages of the autophagy pathway, thus protecting HIV or its biosynthetic intermediates
from autophagic destruction. The net effect of Nef may at first appear akin to that of
herpes simplex virus type 1 protein ICP34.5, which binds to Beclin 1 and inhibits its
function in autophagy [18]. However, the action of Nef is preferentially related to the
maturation stages of the autophagosomal pathway, as shown in our work. Recent studies
have indicated that Beclin 1-hVPS34 complexes in mammalian cells include potential
equivalents of yeast Atg14 [133], which appears to be autophagy initiation specific, and
VPS38 (UVRAG), which acts at maturation and possibly initiation stages [129]. Thus,
different parts of the autophagic pathway may be targeted by viral factors affecting
Beclin 1: autophagy initiation or maturation as in the case of ICP34.5 [18], and Nef (this
paper). Our findings also provide a functional and molecular basis for the results of a
recent comprehensive siRNA screen in HeLa cells identifying among >250 host genes
several Atg factors as playing a role in the HIV life cycle [33].

It has been previously reported [120, 121] that chronic treatment (for 3-7 d) of cells with
low concentrations of rapamycin, which do not induce autophagy, may inhibit viral
replication. The use of rapamycin in our study was limited to acute doses inducing
autophagy, as we used rapamycin only as one of the agents to study how autophagy
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affects viral yields, irrespective of any long term effects that rapamycin may have on
viral replication.

Furthermore, induction of autophagy either with rapamycin or by

starvation (unpublished data) both increased HIV yields, provided that the virus encoded
Nef. Our work nevertheless indicates that, when unopposed by Nef, autophagy can act as
a cell-autonomous anti-HIV defense. This is likely to be of importance, as autophagy is
induced during HIV infection, as shown here and as recently noted in the context of
TLR7 and TLR8 signaling [97].

In terms of the mechanism of the antiautophagic

degradation action of Nef, we found that the diacidic

174

DD175 motif, responsible for

interactions with the V1 domain of vacuolar H+ ATPase and needed for CD4 downregulation [105], is required for effects of Nef on autophagy.

Hence, the simplest

explanation would be that Nef influences H+ ATPase assembly or activity, precluding
autophagosomal acidification and maturation into autolysosomes. However, although
HIV inhibits acidification of compartments with newly budded virions, the pH effect has
been reported to be independent of Nef [115]. Thus, the protein complex containing Nef
and Beclin 1 may act through a mechanism other than acidification. The effect of Nef on
redistribution of hVPS34 (Fig. 2.6E) to membranes may be related to inhibition of
autophagic maturation.

Within the portfolio of Nef effects, which includes down-regulation of MHC class I and
CD4 cell surface expression, altered T cell activation, and augmented viral infectivity
[104-107], a less understood effect is the Nef-induced accumulation of MVB-like
organelles [134, 135] and emergence of large vacuoles [136]. This phenomenon can now
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be explained at least in part by the inhibition of MVB or amphisome consumption due to
a Nef-dependent blockage of autophagic degradation.

In primary human macrophages, the virus transits through the intracellular compartments
that intersect with autophagy factors such as LC3, as illustrated in Fig. 2.2.

The

intersection between HIV and the autophagic pathway is not limited to conditions when
autophagy is induced to high levels. For example, the HIV precursor protein Gag is
found in complexes with LC3 (Fig. 2.2E) even when macrophages are not
pharmacologically stimulated for autophagy, which indicates engagement of the basal
autophagy in biosynthesis, processing, or assembly of HIV intermediates. In other cell
types, such as 293T cells used to dissect mechanistically molecular aspects of Nef action
in the context of the autophagic pathway, the viral Gag did not show colocalization with
the RFP-GFP-LC3 probe (Fig. 2.5A), reflecting the likely differences in intracellular
trafficking of viral precursors in these cells versus macrophages [110-117]. Nevertheless,
viral Nef did inhibit autophagic maturation even in 293T cells, indicating that this activity
does not necessarily coincide with the location of the viral particles or Gag in relation to
LC3.

This is further underscored by the effects of Atg7 and Beclin 1 knockdowns on total p24
yields in resting macrophages infected with HIV. This effect has been independently
observed in HeLa cells upon knockdown of other Atg factors [33]. The enhancement by
autophagy of HIV yields coincides with the association of Gag with LC3 uncovered in
our work.

Furthermore, our findings of enhanced Gag processing associated with
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autophagy indicate that this process plays a role in promoting certain steps in HIV
biogenesis.

Although autophagy is commonly viewed as a catabolic, degradative

pathway primarily engaged in turning over macromolecules and removing toxic protein
aggregates, or whole or parts of intracellular organelles and pathogens, it can also play a
biosynthetic, anabolic role; this is clearly seen in the Cvt pathway in yeast, where Atg
proteins are needed for completion of a functional vacuole [137, 138].

Nef also inhibits apoptosis and cell death in macrophages [130]. It has been shown that
HIV Env induces death in bystander CD4+ CXCR4+ cells via a temporal succession of
autophagy followed by apoptosis, and that completion of autophagy was a prerequisite
for the execution of the subsequent apoptotic cell death [32]. This effect was recently
narrowed down to gp41 [139]. Based on Nef's ability to inhibit terminal stages of
autophagy, it follows that Nef may protect infected macrophages against cell death, in
addition to guarding virions from autophagic elimination. Extending the life span of
macrophages [130] and protecting virions from degradation may lead to higher HIV
yields that are important for progression to AIDS [99, 101].

Pharmacological

intervention to modulate autophagy in HIV-infected macrophages may help delay or
prevent development of clinical AIDS.

Materials and methods

Cells
For macrophages, human monocytes were prepared from HIV-negative donors by density
gradient centrifugation (400 g for 30 min) through a Ficoll-Hypaque gradient (GE
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Healthcare).

Adherent monocytes were matured into macrophages for 7 d before

infection. THP-1 and U937 cells were maintained in RPMI supplemented with glucose,
glutamine, Hepes, and pyruvate.

HeLa and 293T cells were maintained in DME

supplemented with glutamine and FBS. MAGI cells were obtained from the National
Institutes of Health AIDS reagent program.

Antibodies and chemicals
Atg7 and Beclin 1 antibodies were obtained from Santa Cruz Biotechnology, Inc.;
monoclonal p24 antibody was obtained from Novus Biologicals; LC3 antibody was
obtained from T. Ueno (Juntendo University School of Medicine, Tokyo, Japan) or from
Sigma-Aldrich, and Atg12 antibody was obtained from N. Mizushima (Tokyo
Metropolitan Institute of Medical Science, Tokyo, Japan); and the GAPDH antibody was
obtained from Abcam. Gag monoclonal p17 and actin antibodies were obtained from
Abcam. Secondary Alexa Fluor 488- and 568-conjugated antibodies were obtained from
Invitrogen. Gag rabbit polyclonal antibody was obtained from the National Institutes of
Health AIDS reagent program. Rapamycin, 3MA, bafilomycin, and lipopolysaccharide
were obtained from Sigma-Aldrich.

Autophagy methods
Autophagy was triggered by treatment with 25-50 ng/μl rapamycin for 5 h in full nutrient
medium. Alternatively, autophagy was induced by amino acid and serum starvation.
Cells were washed three times with PBS and incubated in 1 ml Earle's balanced salts
solution (starvation medium) at 37°C for 5 h. Autophagy was quantified by the GFP-
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LC3 puncta, LC3-I-to-LC3-II conversion, and proteolysis assays.

Autophagy was

inhibited with 10 mM 3MA. Where used, bafilomycin A1 was at a concentration of 100
nM. Cells were transfected or cotransfected with GFP-LC3, RFP-GFP-LC3, DsRed2,
Nef-DsRed2 (Nef-DsRed2 was provided by K. Collins, University of Michigan, Ann
Arbor, MI) and other constructs for 24 h. The total number of puncta (≥ 1μm) per cell
was counted.

HIV extracellular yield
Methods to monitor HIV p24 yields are described in the legend to Table A2. For
experiments with H9 T cells infected with live virus, the RT-PCR-based assay EnzChek
(Invitrogen) was used to measure reverse transcription activity. Assays were performed
according to manufacturer's instructions. Relative viral release was calculated as the ratio
of extracellular-to-intracellular reverse transcription activity [119, 140-142].

Transfections and infections
Cells were transfected using the nucleoporation protocol (Amaxa) as described
previously [143], with 10 μg of DNA or 1.5 μg of siRNA, as required. Atg7 and Beclin 1
knockdown protein was achieved using siGENOME SMART pool (Thermo Fisher
Scientific). All effects of siRNA were compared with siCONTROL nontargeting siRNA
pool (Thermo Fisher Scientific). For VSV-G pseudotyped HIV infections, U937 cells
were differentiated overnight with 50 ng/ml of phorbol 12-myristate 13-acetate (SigmaAldrich), and viral infections were performed as described previously [130]. MDM were
infected with 105 tissue culture infectious dose of SF162. Infections were allowed to go
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for 10 d with replacement of media every other day. Supernatants from these cells and
cell lysates were frozen at -70°C until used for p24 ELISA or MAGI assays. The MAGI
assay for HIV infectivity was performed as described previously [144]. HIVLAI [145,
146] was expanded for 8 d in H9 T cells as previously described [140]. Supernatants
from these cells were used to infect H9 T cells for experiments using titers as described
by Prasad and Kalpana (2009) [119].

Fluorescence microscopy and image acquisition
Cells were fixed for 10 min with 1% paraformaldehyde, washed with PBS, and, when
immunostained, permeabilized with 0.1% Triton X-100. Secondary antibody controls
were routinely performed and showed no similarity to the pattern obtained when the
primary antibody was included.

Images were taken and processed on a confocal

microscope system (META; Carl Zeiss, Inc.), equipped with 63x 1.4 NA oil differential
interference contrast Plan-Apochromat objective, using Immersol (n = 1.518) at room
temperature. Acquisition software was LSM 510, expert mode (Carl Zeiss, Inc.). Images
were processed by Photoshop (Adobe) using proportional adjustments.

Electron and immunoelectron microscopy
Electron microscopy or viral budding in HIV-infected cells was performed as follows:
control or U937 cells infected with VSV-G-pseudotyped pMSMBA were fixed with 3%
formaldehyde (from paraformaldehyde) + 2% glutaraldehyde in 0.1 M cacodylate, pH
7.4. Cells were then washed and postfixed in 1% osmium tetroxide, 100 mM cacodylate
buffer; dehydrated with increasing concentrations of ethanol; and gradually infiltrated
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with epon resin, embedded in straight resin, and examined using a transmission electron
microscope (EM 900; Carl Zeiss, Inc.). Immunoelectron microscopy was performed
using rabbit polyclonal LC3 antibody [147], applying the preembedding gold
enhancement method as described previously [148]. U937 cells cultured on plastic
coverslips (LF; Sumitomo Bakelite) were fixed with 4% paraformaldehyde (Nacalai
Tesque) in 0.1 M sodium PBS, pH 7.4, for 30 min. After washing with the same buffer
three times for 5 min, the fixed cells were permeabilized using 0.25% saponin in PBS.
The cells were washed with PBS, blocked by incubating for 30 min in PBS containing
0.1% saponin, 10% BSA, 10% normal goat serum, and 0.1% cold water fish skin gelatin,
then exposed overnight to 0.01 mg/ml of anti-LC3 rabbit polyclonal antibody or 0.01
mg/ml of nonimmunized rabbit IgG in the blocking solution. After washing with PBS
containing 0.005% saponin, the cells were incubated with colloidal gold (1.4-nm
diameter; Nanoprobes)-conjugated goat anti-rabbit IgG in the blocking solution for 2 h.
The cells were then washed with PBS and fixed with 1% glutaraldehyde in PBS for 10
min. After washing with 50 mM glycine in PBS, 1% BSA in PBS, and finally with
milliQ water (Millipore), gold labeling was intensified with a gold enhancement kit
(GoldEnhance EM; Nanoprobes) for 3 min at room temperature according to the
manufacturer's instructions. After washing with distilled water, the cells were postfixed
in 1% OsO4 containing 1.5% potassium ferrocyanide in PBS for 60 min at room
temperature, and washed with distilled water. The cells were dehydrated in a series of
graded ethanol solutions and embedded in epoxy resin. After the epoxy resin hardened,
the plastic coverslip was removed from it. Ultrathin sections were cut horizontally to the
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cell layer and double stained with uranyl acetate and lead citrate. Samples were analyzed
with an electron microscope (H7600; Hitachi).

Western blots and immunoprecipitations
Cells were washed in PBS and lysed with buffer containing 10 mM Tris HCl, pH 8.0, 150
mM NaCl, 0.5% deoxycholate, 2 mM EDTA, 2% NP-40, 1 mM PMSF, and protease
inhibitor cocktail (Roche). 50 μg of protein was loaded and separated on a 12.5% SDSpolyacrylamide gel and transferred to nitrocellulose.

The membrane was blocked

overnight at 4°C in 5% milk in PBS/Tween 20 (0.1%) and probed with primary
antibodies for 1 h at room temperature. After washing with PBS/Tween, the blot was
probed with appropriate HRP-conjugating secondary antibody for 1 h at room
temperature and stained with SuperSignal West Dura chemiluminescent substrate from
Thermo Fisher Scientific.

GAPDH was used as a loading control.

For

immunoprecipitations, transfected 293T cells were lysed with lysis buffer (50 mM TrisHCl, pH 7.4, 150 mM NaCl, 1% nonidet P-40, 0.25% sodium deoxycholate, and 1 mM
EDTA, with protease and phosphatase inhibitors) for 1 h, followed by centrifugation to
remove cell debris. Supernatants were precleared and incubated for 2 h with rabbit antiBeclin 1 (Novus Biologicals), anti-LC3B, or rabbit anti-GFP (Abcam) at 4°C. The
immune complexes were captured with protein G-agarose beads (EMD) overnight at 4°C.
Immunoprecipitates were washed four times with PBS, eluted with Laemmli SDS-PAGE
sample buffer for 5 min at 100°C, and subjected to immunoblot analysis with mouse antiNEF (United States Biological), goat anti-Beclin 1 (Santa Cruz Biotechnology, Inc.), and
mouse anti-GFP (Abcam). Note, in immunoprecipitation experiments with the
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154

EE155

→

154

QQ155 Nef mutant, this Nef variant consistently showed anomalous electrophoretic

mobility.

Subcellular fractionation and cytosol preparation
U937 cells were infected with VSV-G-pseudotyped HIV for 2 d. Cells were lysed by
passage through a tubing-interconnected two-syringe apparatus, and nuclei were cleared
by low-speed centrifugation. The postnuclear supernatant was put on 20, 30, 40, 45, 50,
55, and 60% sucrose gradients, then centrifuged overnight at 100,000 g. 12 fractions
collected from the top were pelleted at 100,000 g for 1 h and immunoblotted for the
indicated organellar markers.

Appendix supplemental material
Fig. A1 shows that Atg7 and Beclin 1 knockdowns inhibit autophagy in U937 cells, as
well as transmission and immunoelectron micrograph HIV profiles in macrophages. Fig.
A2 shows a comparison of LC3 forms in whole cell lysate versus LC3 forms associated
with membranes, that autophagy induction is operational in cells used to detect HIV
yield-enhancing effects of acute rapamycin treatment, and that Nef causes accumulation
of LC3 puncta. Fig. A3 shows that Nef inhibits autophagic proteolysis; intracellular
localization of Nef relative to mTOR, 2xFYVE-GFP, and autophagy markers Atg7,
Atg12, and Beclin 1; and that Nef motif
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DD175 is but G2A motif is not required for

Nef-dependent increase in LC3II levels. Table S1 shows HIV molecular clones, viruses,
and viral preparations and use. Table A2 shows ELISA (p24) and quantification of viral
release. Online supplemental material is available at http://www.jcb.org/cgi/content/full/j
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CHAPTER 3

AUTOPHAGY-MEDIATED RESTRICTION OF HIV-1 BY RHTRIM5α
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Abstract

With a broad spectrum of physiological and medical consequences, autophagy controls
cytosolic and organellar quantity and quality through the capture of intracellular targets
into autophagosomes for subsequent degradation in autolysosomes [5]. Among diverse
immune functions, autophagy acts as a cell-autonomous process by capturing and
eliminating intracellular microbes [5, 85]. Recently, autophagy has been identified as a
process that can inhibit HIV-1 in infected cells at stages when it is unopposed by HIV-1
anti-autophagic factors [149, 150]. Although HIV-1 is the leading cause of acquired
immunodeficiency syndrome (AIDS) in humans, it does not cause disease in certain
species of monkeys [34], due in part to the existence of restriction factors. The recently
identified rhesus macaque restriction factor, RhTRIM5α, has been shown to specifically
bind HIV capsid and lead to degradation of the viral core by an unknown mechanism
immediately after fusion and release of the core into the cytosol [40]. Here we show that
RhTRIM5α acts through autophagy to restrict HIV-1, leading to its degradation soon
after infection. This restriction requires the autophagy factors p62 [12], LC3 [151],
Beclin 1 and Atg7, thereby revealing the preferred target for restriction of HIV-1 by
RhTRIM5α. We furthermore uncover an inability of human TRIM5α to bridge HIV
capsid to autophagy, of possible significance to the susceptibility of humans to HIV-1
infection.
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Results

In addition to roles in homeostasis and disease states, autophagy enables eukaryotes to
defend against dangerous invaders, such as viruses, bacteria, and likely protozoa and
fungi as well. Autophagy specifically recognizes and encloses microbes in a double
membrane vacuole called an autophagosome, which then fuses with lysosomes to
degrade and clear the threat from host cells [5]. During capture of targets slated for
destruction, autophagy typically employs a variety of adaptor proteins, including p62
(also called sequestosome 1) [12].

P62 has recently been shown to associate with

RhTRIM5α [152], but the possible contribution of p62-mediated autophagy to
RhTRIM5α restriction of HIV-1 has not been considered. Already the contribution of
autophagy to HIV pathogenesis has been shown in human cells [149, 150], but there
remains the need for investigation into the role of autophagy in non-permissive nonhuman primates. Thus, delivery of incoming HIV-1 core particles to autolysosomes as a
possible mechanism for RhTRIM5α-mediated restriction of HIV was explored in this
study.

To investigate the possibility that restriction of HIV-1 by RhTRIM5α could be
autophagy-mediated, a panel of inhibitors was tested for an ability to block degradation
of the viral core (as measured by p24 capsid protein immunoblotting) during acute
infection (Fig. 3.1). Monkey cells (FRhK4) endogenously expressing RhTRIM5α were
infected with VSVG-pseudotyped HIV-1 in the presence of these inhibitors for 4 hours,
prior to peak viral integration and de novo replication [153]. Both lysosomal inhibitor,
bafilomycin A1 (an inhibitor of the vacuolar ATPase, labeled "Baf" in the figure), and
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Figure 3.1. Lysosomal inhibitors block degradation of HIV in RhTRIM5α expressing cells. (A)
FRhK4 monkey cells were infected with VSVG-pseudotyped HIV in the presence of vehicle control
(CT or CTR), bafilomycin A1 (Baf) or e64d and pepstatin A (e64d + pepA). After 4 hours, the cells
were collected and lysed. Whole cell lysates were Western blotted to detect the amount of remaining
p24 after treatment. (B) FRhK4 cells were infected in the presence of either vehicle control (CT or
CTR), bafilomycin A1 (Baf), lactacystin (Lac), MG132, or a combination of two and Western blotted
as in A for the amount of p24 that was not degraded. Recovery of HIV for both graphs is expressed
as the amount of p24 over the amount of actin (used as a loading control). Quantifications of p24 and
actin for graphical analyses are explained in the materials and methods section. Both graphs represent
at least three independent experiments. Asterisks indicate significance compared to control (p-value
< 0.05, student's t-test). Error bars indicate ±SEM.

lysosomal protease inhibitors, e64d and pepstatin A (labeled "e64d+pepA"), protected
HIV capsid (p24) from elimination in monkey cells (Fig. 3.1A). Recovery of p24 in the
presence of lysosomal inhibitor bafilomycin was greater than the recovery of p24 in the
presence of proteasome inhibitors, lactacystin (labeled "Lac") or MG132, indicating that
the contribution of lysosomes to degradation of HIV is greater than that of the
proteasome (Fig. 3.1B). The same protective effect on p24 by bafilomycin was also seen
in HeLa cells stably expressing HA-tagged RhTRIM5α (HA-RhTRIM5α cells) (Christina
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Dinkins and George Kyei, unpublished). To definitively determine whether HIV core
particles were being degraded by autophagy, as a route to lysosomal degradation, monkey
cells were infected with HIV after knockdown of key autophagy initiators, Beclin 1 or
Atg7, using siRNA. Beclin 1 is a master regulator of autophagic membrane formation,
while Atg7 is responsible for regulating the conjugation of phosphatidylethanolamine
(PE) to LC3, a protein. PE conjugation allows LC3, in this form called LC3 II, to anchor
into and stabilize the newly forming autophagic membrane, a step essential for membrane
growth. PE unconjugated LC3 is referred to as LC3 I, which is distributed free in the
cytosol [10]. Without Beclin 1 or Atg7, p24 was, similar to bafilomycin treatment, not
significantly degraded, indicating that RhTRIM5α-mediated restriction of HIV requires a
functional autophagy pathway (John Arko-Mensah, unpublished).

In order to distinguish between an indirect effect on autophagy and a direct association
with the autophagic machinery, we next asked if RhTRIM5α colocalized with two
important autophagy factors, adaptor protein p62 and autophagy marker LC3 (Fig. 3.2).
HA-RhTRIM5α cells were transiently transfected with either p62-GFP or LC3-GFP and
immunostained for HA-RhTRIM5α via the HA tag. Normally, transiently transfected
p62 or LC3 will appear as punctate structures in confocal microscopy images [154, 155].
P62 puncta indicate pre-autophagic and autophagic macromolecular complexes (in other
words, structures which may or may not contain membrane, but are in transit to
autophagy), whereas LC3 puncta specifically designate autophagic membrane as a
function of LC3 II's ability to associate with membrane.

In HA-RhTRIM5α cells,

colocalization between RhTRIM5α and transiently transfected p62-GFP was nearly
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Figure 3.2. Autophagy factors colocalize with RhTRIM5α. (A) Confocal microscopy was used to
examine the distribution of RhTRIM5α and autophagy adaptor protein p62. Stably-expressing HARhTRIM5α HeLa cells were immunostained for HA in the presence of p62-GFP, and fluorescently
labeled with the appropriate secondary antibody as described in the Materials and Methods section.
(B) Confocal microscopy was used to examine the distribution of RhTRIM5α and autophagy marker
LC3. HA-RhTRIM5α cells were immunostained for HA and fluorescently labeled as in A and
transfected with LC3-GFP. The inset at the top left of each image shows a magnification of the area
shown in dashed outline. It is included to show a representative example of overlapping areas of
RhTRIM5α and LC3 distributions indicating colocalizations, each region indicated by the white
arrows.

absolute (Fig. 3.2A), indicating that RhTRIM5α and p62 occupy the same subcellular
space. However, when compared to LC3-GFP, only certain populations of RhTRIM5α
were seen to colocalize, perhaps indicating that RhTRIM5α and LC3 potentially occupy
distinct, but overlapping areas within the cell under uninfected conditions (Fig. 3.2B,
inset shows magnification of 4 puncta containing both LC3 and RhTRIM5α).

To determine whether colocalizations of RhTRIM5α with LC3 or p62 represent physical
interactions in a protein complex, co-immunoprecipitation was performed on LC3-GFP
or GFP-p62 transfected HA-RhTRIM5α cells (GFP transfection was used as a negative
control) (Fig. 3.3). LC3-GFP protein was immunoprecipitated from cell lysates using a
GFP specific antibody. The amount of RhTRIM5α in the precipitate was visualized after
61

Figure 3.3. Autophagy factors co-precipitate with RhTRIM5α. (A) Complex formation between
RhTRIM5α and LC3 was assessed by co-immunoprecipitation. HA-RhTRIM5α cells were
transfected with either LC3-GFP or GFP. LC3-GFP or GFP was immunoprecipitated using a GFP
specific antibody. The amount of HA-RhTRIM5α in the precipitate was visualized by Western
blotting using anitbodies specific to the HA tag. (B) Complex formation between RhTRIM5α and
p62 was assessed by co-immunoprecipitation. HA-RhTRIM5α cells were transfected with either
GFP, p62-GFP wt (full length p62), p62-GFP ΔLIR (LIR domain deleted p62), or p62-GFP ΔUBA
(UBA domain deleted p62). The various p62 proteins or GFP were immunoprecipitated using
antibodies to the GFP tag and the amount of HA-RhTRIM5α in the precipitate was visualized by
Western blotting. The graph represents the amount of HA-RhTRIM5α recovered for amount of GFP
immunoprecipitated. For both immunoprecipitation experiments, GFP was used as a negative protein
interaction control, while IgG from unimmunized animals was used as a negative antibody control.

Western blotting using an antibody specific to its HA tag. In precipitates containing
purified LC3-GFP, HA-RhTRIM5α was seen to co-precipitate better with it than when
compared to GFP transfected controls, supporting the idea that a population of
RhTRIM5α associates with LC3 (Fig. 3.3A). When p62 was immunoprecipitated via its
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GFP tag, again RhTRIM5α (via it's HA tag) was seen to co-precipitate with it better than
GFP control (compare amount of RhTRIM5α recovered from GFP versus GFP-p62 wt
immunoprecipitates, Fig 3.3B, blot on right side, first lane and third lane). IgG antibody
from unimmunized animals was used as a control to determine the amount of background
recovery of each protein investigated in these experiments (Fig. 3.3A and B, lanes labeled
"IgG").

P62, also known as sequestosome 1, bridges autophagic targets to the autophagosome
through two direct interactions.

First, p62 recognizes polyubiquitin tags on targets

destined for autophagy through its ubiquitin binding area (UBA). Second, p62 directly
interacts with LC3 through its LC3 interacting region (LIR) (for a review and explanation
of the domains of p62, see Fig. G1). To investigate complex formation requirements
between p62 and RhTRIM5α, we used p62 domain mutants at the same time we did the
GFP-p62 wt immunoprecipitation experiments described above (Fig. 3.3B, last four
lanes). The graph in Fig. 3.3B is an analysis of the above, right blot and shows the
recovery of RhTRIM5α for the amount of p62 protein immunoprecipitated (expressed as
fold change over GFP-p62 wt).

The amount of RhTRIM5α recovered in

immunoprecipitates from cells transfected with either GFP-p62 deleted for LC3 binding
(GFP-p62 ΔLIR) or p62 deleted for ubiquitin binding (GFP-p62 ΔUBA) can be
compared to the amount recovered in the presence of full length p62 (GFP-p62 wt) (Fig.
3.3B, see blot on right side, last six lanes and graphical analysis of the blot, lower left).
RhTRIM5α associated with GFP-p62 wt efficiently (compared to GFP control), but lost
some ability to associate with p62 when it was deficient for LC3 binding (GFP-p62
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ΔLIR) (Fig. 3.3B, see graph, GFP-p62 wt compared to GFP-p62 ΔLIR and blot on right
side, comparing third lane to fifth lane) (supporting data by Manohar Pilli, unpublished).
These results may indicate that complex formation of RhTRIM5α with p62 is supported
by LC3, but in fact, when p62 is knocked down using siRNA, almost no RhTRIM5α can
be seen in LC3 purified immunoprecipitate, indicating that RhTRIM5α association with
LC3 instead requires p62 (Marisa Ponpuak, unpublished data). This is consistent with
the microscopy data that shows RhTRIM5α preferentially localizes to regions containing
p62, while only partially overlapping with regions containing LC3, suggesting that
RhTRIM5α may form a complex with p62 first and then associate with LC3 as needed.
Therefore, the requirement for the LIR domain of p62 may reveal a unique binding site
for RhTRIM5α. Interestingly, it has been published that p62 binds to the RING domain
of TRAF6 (involved in the NFκB pathway) through a span of amino acids that partially
overlaps with the amino acids deleted in the LIR domain mutant used in this study [156].
Thus, it is possible that p62 also binds to the RING domain of RhTRIM5α through the
same binding site. Finally, when the ubiquitin binding domain was deleted from p62
(GFP-p62 ΔUBA), RhTRIM5α, surprisingly, appeared to associate better with it (Fig.
3.3B, see graph, GFP-p62 wt compared to GFP-p62 ΔUBA and blot on right side,
comparing third lane to seventh lane). This result may reflect some kind of competition
for p62 between ubiquitinated proteins at the UBA domain and RhTRIM5α near the LIR
domain.

When colocalization of RhTRIM5α with endogenous p62 and LC3 was investigated
using confocal microscopy (Fig. 3.4), RhTRIM5α minimally colocalized with LC3 under
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Figure 3.4. Endogenous autophagy factors colocalize with RhTRIM5α. (A) The degree of
colocalization between RhTRIM5α and endogenous autophagy factors were evaluated in HARhTRIM5α cells using indirect immunofluorescence. HA-RhTRIM5α cells were immunostained for
HA-RhTRIM5α, LC3 and p62 under control (CTR) and rapamycin (RAP) treated conditions. Graphs
represent amount of colocalization between RhTRIM5α and LC3 or p62, expressed as Pearson's
coefficient of colocalization, among 4 cells. All indirect immunofluorescence labeling procedures are
explained in the Materials and Methods section.

basal autophagy, control conditions (Fig. 3.4A, see fluorescent images and graph on
right, LC3 control (CTR)). However, RhTRIM5α colocalization with LC3 could be
induced by stimulating autophagy with rapamycin treatment (Fig. 3.4A, images and
graph on right, LC3 rapamycin (RAP)). Rapamycin is a pharmacological stimulator of
autophagy and was used to induce autophagy to an elevated state where the rate of
autophagic flux is maximized. These data suggest, with the co-immunoprecipitation data,
that RhTRIM5α may associate with the autophagic machinery in response to stimuli
inducing autophagy, perhaps indicating that infection with HIV could induce the same
movement of RhTRIM5α to autophagosomes. When colocalization of RhTRIM5α with
p62 was analyzed, it was found that RhTRIM5α colocalized with p62 without
pharmacological induction of autophagy (Fig. 3.4B).

The amount of colocalization

among proteins was analyzed by measuring the Pearson's coefficient of colocalization, a
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measure of the amount of overlap of two fluoroscences per given object (puncta, ≥ 0.25
μm2, 0 indicates no colocalization, while -1 and 1 indicate negative and positive
colocalization, respectively). All fluorescent labeling in the study was done by indirect
immunofluorescence as is described in the Materials and Methods section. Otherwise,
fluorescence was visualized as a result of GFP fusion protein expression and not labeled
(as in Fig. 3.2).

Next, confocal microscopy was used examine the distribution of HIV capsid (as
measured by p24 immunolabeling) with p62 and LC3 in the presence of RhTRIM5α (Fig.
3.5). HA-RhTRIM5α cells or monkey cells were infected with HIV for 4 hours then
fluorescently labeled for endogenous autophagy factors p62 and LC3. Colocalization of
p62 and LC3 was compared to HIV p24 distribution, also fluorescently labeled. The
Pearson's correlation coefficient (R) of colocalization between p24 and p62 in the
monkey cells was 0.45, indicating positive colocalization, whereas the correlation of
colocalization between p24 and LC3 was less at 0.21, although still positive (Fig. 3.5A).
When compared to HA-RhTRIM5α cells, colocalization between p24 and p62 or LC3
increased (Fig. 3.5B, RRhTRIM5α/p62 = 0.49, RRhTRIM5α/LC3 = 0.32). These results indicate
that association of HIV capsid with autophagy increases in a RhTRIM5α dose dependent
manner, as stably expressing HA-RhTRIM5α in HeLa cells results in a greater expression
level (about 1.6 fold increase) as compared to endogenous RhTRIM5α in monkey cells.
To definitively determine whether RhTRIM5α-mediated restriction of HIV was p62
dependent, p62 was knocked down using siRNA during infection. In the absence of p62,
HIV could not be significantly degraded (John Arko-Mensah, unpublished). Finally,
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Figure 3.5. HIV colocalizes with autophagy in the presence of RhTRIM5α. (A) FRhK4 monkey
cells were infected with HIV and immunostained for HIV p24, LC3 and p62. Colocalizations
between HIVp24 and LC3 or p62 were quantified (graph on the right). (B) HA-RhTRIM5α HeLa
cells were infected with HIV and immunostained for HIV p24, LC3 and p62. Colocalizations
between HIV p24 and LC3 or p62 were quantified (graph on the right). Graphs represent amount of
colocalization between p24 and LC3 or p62, expressed as Pearson's coefficient of colocalization,
among 9-15 objects (p24+ and LC3+ or p62+ puncta).

when HeLa cells not expressing RhTRIM5α were infected with HIV, no overlap in
localization was seen between p24 and p62. In the absence of RhTRIM5α, HIV p24
distributed in a perinuclear fashion while p62 remained in the cytosol and, interestingly,
did not form the puncta seen in previous experiments (Fig. 3.6).
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Figure 3.6. HIV does not colocalize with autophagy protein p62 in the absence of RhTRIM5α.
(A) HeLa cells were infected with HIV and immunostained for HIV p24, p62, and HuTRIM5α.
Colocalization between p24 and p62 or HuTRIM5α was not analyzed.

These results indicate that autophagy may be the primary target for degradation of
incoming HIV core particles through capsid recognition by RhTRIM5α and subsequent
engagement with the autophagic machinery. The specific recognition of HIV capsid that
is unique to RhTRIM5α, while impaired with HuTRIM5α, may reveal a loss in the link
between HIV and autophagy in human cells. The requirement of RhTRIM5α for HIV
association with the autophagy adaptor p62 suggests that the failure of autophagy to
recognize HIV capsid in the presence of HuTRIM5α may be a reflection of the inability
of HuTRIM5α to significantly associate with HIV capsid.

The consequences of

recognition failure to autophagic capture are best demonstrated by the experiment
showing that HIV cannot associate with the autophagy adaptor p62 in the absence of
RhTRIM5α, while in the presence of HuTRIM5α. As the mechanism of restriction by
RhTRIM5α is further elucidated, it may become a viable target for therapeutic
intervention perhaps through pharmacological manipulation of autophagy or through
promoting the recognition of HIV core by autophagy.
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Materials and Methods
Cells and virus
HeLa cells stably expressing HA-RhTRIM5α were kindly provided by Joseph Sodroski.
These cells were maintained in complete DMEM media containing 1 μg/ml of puromycin
as a positive selection agent [40]. FRhK4 cells were used as a rhesus macaque model of
endogenous RhTRIM5α restriction [76], and were purchased from ATCC. They were
maintained in complete DMEM. VSV-G pseudotyped HIV-1 was prepared from cotransfection of plasmids encoding NL4.3Δenv HIV-1 (NIH) and vesicular stomatitis virus
G protein into HEK 293T cells. Supernatants from these cells were used to infect HARhTRIM5 HeLa, HeLa or FRhK4 cells for experiments using titers as previously
described (Chapter 2).

Infection and drug treatments
All experiments with HIV infection were synchronized at 4°C for 1 hour.

After

synchronization, cells were washed 2-3 times with cold 1x PBS before experimental
treatment in full media. Cells were then incubated in treatment conditions at 37°C for 4
hours. For the various drug treatments the following concentrations were used: 100 nM
bafilomycin Al, 50 μg/ml rapamycin, 10 μg/ml e64d and 10 μg/ml pepstatin A, 10 μM
lactacystin, and 10 μM MG132 as previously described [155]. Stocks of the various
pharmacological agents were diluted to their final concentrations using DMSO. DMSO
was used as a control for all drug treatment experiments.

Immunoblotting and immunoprecipitation

69

Whole cell lysates were collected and lysed in a non-denaturing buffer containing
protease inhibitors. Lysis was performed either by freeze fracturing overnight at -70°C
for immunoblotting or by incubating the samples on ice for 30 minutes for
immunoprecipitations. The lysis buffer was composed of 1% Triton X-100, 50 mM TrisHCl (pH 7.4), 300 mM NaCl, and 5 mM EDTA. Protease inhibitors were added to the
lysis buffer at the following final concentrations: 100 μM leupeptin, 1 μM pepstatin A, 10
μM e64 and 100 μM TLCK. Whole cell lysates were then prepared for immunoblotting
with Laemmli buffer or diluted for immunoprecipitation. For immunoblotting, 50 μg of
protein for each sample was separated on a 15% polyacrylamide gel and transferred to
nitrocellulose. Immunoblotting was then performed as previously described (Chapter 2).
The following primary antibodies were used for immunoblotting: mouse anti-p24
(Abcam), rabbit anti-LC3 (Sigma), mouse anti-actin (Abcam or Sigma), rabbit antiTRIM5α (Imgenex), mouse or rabbit anti-HA (Abcam or Sigma, respectively), mouse
anti-GFP (Abcam), and guinea pig anti-p62 (Progen). For immunoprecipitations, 0.5-1.5
mg of protein was diluted in ice cold PBS containing protease inhibitors in concentrations
as described above.

Samples were then pre-cleared on protein G agarose beads

(Calbiochem) using non-specific rabbit IgG. Immunoprecipitation was then performed
on Invitrogen Dynabeads® Protein G for IgG capture using rabbit anti-GFP (Abcam) for
samples and non-specific rabbit IgG for controls. The procedure for immunoprecipitation
was then performed as previously described (Chapter 2).

Fluorescence microscopy and image acquisition
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The immunofluorescence procedure was performed as previously described (Chapter 2).
The following primary antibodies were used for immunostaining: mouse anti-HA
(Covance), guinea pig or sheep anti-p62 (Progen or Abcam, respectively), rabbit antiLC3 (MBL), rabbit anti-TRIM5α (Abcam), and mouse anti-p24 (Abcam). The following
secondary antibodies (Invitrogen) were used for immunofluorescence: Alexa Fluor 488
for green, Alexa Fluor 568 for red, and Alexa Fluor 647 for blue. Images were taken and
processed on a confocal microscope system (META; Carl Zeiss, Inc.), equipped with 63x
1.4 NA oil differential interference contrast Plan-Apochromat objective, using Immersol
(n = 1.518) at room temperature. Acquisition software was LSM 510, expert mode (Carl
Zeiss, Inc.).

Images were processed by Adobe Photoshop using proportional

adjustments.

Visual and statistical analyses
Western blot band intensity was measured using the Image J software provided by NCBI.
Recovery of p24 was calculated as the band intensity of p24 divided by the band intensity
of actin per sample. Actin was used as a loading control. Recovery of HA-RhTRIM5α
was calculated as the band intensity of HA-RhTRIM5α divided by band intensity of GFP
or p62-GFP (wt, ΔLIR or ΔUBA) over band intensity of p62-GFP wt. The colocalization
of fluorescent objects (puncta, ≥ 0.25 μm2) on microscopy images were measured by
calculating the Pearson's correlation coefficient (R) between fluorescence intensities
using Slidebook 5.0 (Intelligent Imaging Innovations, Inc.).

"0" indicates no

colocalization. Values above 0 indicate positive colocalization. Colocalizations were

71

measured among cells or objects as described in the figure legends. Significance was
determined by performing a student's t-test, p-value < 0.05.
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CHAPTER 4

TRIM5α IS AN INNATE IMMUNITY REGULATOR INDUCING AUTOPHAGY
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Abstract

Defense against intracellular pathogens is a key feature of higher order eukaryotes.
Complex mechanisms have evolved to protect the organism from parasitic infection.
These protective mechanisms can be categorized as part of the immune system, falling
into two basic groups: innate and adaptive immunity. Within the innate and adaptive
immune systems, autophagy, as a degradative process, contributes to defense against
pathogens in a variety of ways [5]. One way in which autophagy contributes to antimicrobial defense is through the direct elimination of pathogens. Prerequisite to this
capture and clearance by autophagy is believed to be the recognition of pathogens
through a set of pattern recognition receptors (PRRs) [16]. After recognition of the
pathogenic information, the innate immunity machinery may then activate the autophagy
pathway. TRIM proteins are increasingly gaining attention as a unique class of innate
immunity regulators [44], with a variety of TRIM's capable of recognizing specific
pathogens [43]. However, induction of autophagy by TRIM proteins as a function of
their roles in innate immunity has yet to be investigated. Here we report TRIM5α as a
unique autophagy regulator capable of engaging the autophagic machinery. Furthermore,
we find supporting evidence that induction of autophagy by TRIM5α occurs through the
generation of K63 type polyubiquitin chains.
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Results

After infection with an intracellular microbe, two steps must occur for the upregulation of
autophagy.

First, pattern recognition receptors (PRRs) must recognize pathogen-

associated molecular patterns (PAMPs) and activate a signaling cascade that induces the
innate immune response.

Second, the innate immunity machinery (through a new

signaling cascade) must respond to these signals by upregulating the autophagy pathway.
The TRIM family of proteins represent a unique class of innate immunity factors
implicated in both stages of the antimicrobial response [44, 59-61].

To investigate the possibility that TRIM5α may be capable of connecting innate
immunity to autophagy, its ability to affect autophagy independent of infection was tested
by measuring the amount of LC3 II due to the overexpression of TRIM5α (Fig. 4.1).
LC3 II is an autophagy factor required for membrane stabilization and growth during
autophagosome formation, the basic physical component of autophagy. LC3 exists in the
cell in two forms: the LC3 I form, which is distributed free in the cytosol, and the LC3 II
form, converted from LC3 I, and phosphatidylethanolamine (PE) lipidated. Conversion
of LC3 I to LC3 II, regulated by other autophagy factors, reflects the rate of autophagic
flux. During states of elevated autophagic flux (i.e. induction), LC3 I is converted to
LC3 II at a higher rate than at basal autophagy levels. In this experiment, HeLa cells
were transfected with human TRIM5α-GFP (HuT5-GFP), rhesus TRIM5α-GFP (RhT5GFP), or GFP as a control. Transfection with either TRIM5α resulted in an increase in
LC3 II compared to GFP control (HuT5-GFP CT and RhT5-GFP CT compared to GFP
CT, Fig. 4.1A, blot and graph), indicating that TRIM5α proteins do have an effect on
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Figure 4.1. TRIM5α can induce autophagy. (A) HeLa cells were transfected with either GFP,
human TRIM5α-GFP (HuT5-GFP), or rhesus TRIM5α-GFP (RhT5-GFP) in the presence or absence
of bafilomycin A1. The levels of LC3 II that accumulated due to these treatments and transfections
are graphically represented as the amount of LC3 II over the amount of actin (used as a loading
control). The graph represents data from three independent experiments. Asterisks indicate
significance among the data sets compared (indicated by brackets) (p-value <0.05, student's t-test).
Error bars indicate ±SEM.

autophagy. Because the accumulation of LC3 II may be due to either an increased rate of
conversion from LC3 I to LC3 II (caused by induction) or an impaired degradation of
LC3 II (caused by a block in autophagic maturation), bafilomycin A1 was used to inhibit
autophagic maturation, thereby controlling for possible effects on maturation and
allowing distinction between the two.

Treatment with bafilomycin A1 resulted in

significantly higher levels of LC3 II in the presence of both TRIM5α compared to GFP
alone, indicating that the accumulation of LC3 II in untreated conditions is due to an
elevated rate of conversion from LC3 I to LC3 II (i.e. induction of autophagy) (HuT5GFP Baf and RhT5-GFP Baf compared to GFP Baf, Fig. 4.1A, graph).

A common feature of all TRIM proteins is that they contain RING domains. Many of
these RING domains have been shown to have E3 ubiquitin ligase activity, including
human and rhesus TRIM5α [50]. Some of these TRIMs have been shown to be capable
of generating K63 type polyubiquitin chains [62, 63, 72, 73]. This type of polyubiquitin
chain describes ubiquitin proteins sequentially linked through lysine residues at amino
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acid position 63. Interestingly, some studies have indicated that autophagy adaptor
protein p62 itself prefers this kind of lysine linkage through its UBA (ubiquitin binding
area) domain and traffics proteins tagged with K63 type polyubiquitin chains to
autophagy [64, 66-68]. Therefore, the possibility of an interaction between TRIM5α and
p62 was investigated through a co-immunoprecipitation experiment (Fig. 4.2). HeLa
cells stably expressing either human HA-TRIM5α (HA-HuTRIM5α) or rhesus HATRIM5α (HA-RhTRIM5α) were lysed and immunoprecipitated for TRIM5α protein
using an antibody specific to the HA tag.

From purified TRIM5α precipitates,

endogenous p62 was found in complex with both variants of the TRIM5α protein upon
immunoblotting (Fig. 4.2A). These results might suggest a role for TRIM5α in directly
regulating autophagy through association with p62.

Next, to determine whether there was an association of TRIM5α with polyubiquitin and
to evaluate the kind of polyubiquitin linkage, a final immunoprecipitation experiment was
performed (Fig. 4.3). HeLa cells stably expressing HA-RhTRIM5α were lysed and
immunoprecipitated for the TRIM5α protein as described above. When TRIM5α was
purified, an abundance of K63 type polyubiquitin chains were found to associate with it.
The blot was then stripped and probed for the presence of another type of polyubiquitin
chain (K48, thought to be a signal for proteasomal degradation). K48 polyubiquitin
chains were not detected and therefore cannot be confirmed to associate with TRIM5α.

K63 type polyubiquitination has been found to specifically promote protein inclusion
formation [68, 71], which has been implicated in p62-mediated trafficking of targets to
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Figure 4.2. TRIM5α forms a complex with autophagy adaptor protein p62. (A) HA-TRIM5α
was immunoprecipitated from HeLa cells stably expressing either human TRIM5α or rhesus TRIM5α
and the amount of endogenous p62 in the precipitate was visualized by Western blotting.

autophagy [66, 67]. This type of polyubiquitin, found in association with RhTRIM5α,
might indicate a mechanism whereby either TRIM5α variant could promote the formation
of pre-autophagic aggresomal structures (as a function of their homologous RING
domains) in response to some stimulus (such as HIV-1 infection in the case of the rhesus
macaque variant), then attract p62 for targeted upregulation of autophagy. To fully
understand the contribution of p62 and K63 type polyubiquitin to TRIM5α-mediated
induction of autophagy, it will first be important to show whether or not these factors are
definitively required for TRIM5α's effects. Part of this understanding will also require
investigation into the nature of the association between TRIM5α and p62 and K63
polyubiquitin, especially direct versus indirect interactions. It is possible that the target
for K63 polyubiquitination is not TRIM5α, as one could predict, but perhaps another
factor involved in regulating autophagy. The identification of other factors involved in
TRIM5α's effects on autophagy will help us to elucidate the mechanism of autophagic
induction by TRIM5α and may reveal new targets for therapeutic intervention of HIV and
possibly other diseases.

An important indicator of a possible role for TRIM5α in promoting pre-autophagic
aggresomal formation is revealed by overexpression of either human or rhesus TRIM5α,
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Figure 4.3. TRIM5α forms a complex with K63 type polyubiquitin. (A) HA-TRIM5α was
immunoprecipitated from HeLa cells stably expressing rhesus TRIM5α and the amount of K63 type
polyubiquitin in the precipitate was visualized by Western blotting.

where they are seen to distribute in the cell as punctate structures called cytoplasmic
bodies [48]. These structures may reflect TRIM5α's propensity for aggresome-based
autophagic induction, revealing another possible target for therapeutic intervention during
HIV infection through the control of cytoplasmic body formation.

Interestingly,

expression of TRIM5α can be upregulated through IFNβ treatment. Indeed, future studies
with IFNβ may prove an effective new treatment for infected individuals.

Materials and Methods

Cells
HeLa cells stably expressing either human or rhesus HA-TRIM5α were kindly provided
by Joseph Sodroski. These cells were maintained as previously described (Chapter 3).

Plasmid constructs and drug treatment
Plasmids encoding human or rhesus TRIM5α-GFP were a kind gift from Joseph
Sodroski. Transfections were performed as previously described (Chapter 2). For the
bafilomycin A1 study, cells were treated with either 100 nM bafilomycin A1 or vehicle
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as a control for 4 hours then collected for Western blotting. Stocks of bafilomycin A1
were diluted in DMSO. DMSO was used as a control.

Immunoblotting and immunoprecipitation
Cells were collected and lysed as previously described (Chapter 3). Immunoblotting and
immunoprecipitation protocols were performed as previously described (Chapter 2 & 3).
For immunoprecipitations, rabbit anti-HA antibody was used to precipitate HA-TRIM5α.
Non-specific rabbit IgG was used as an immunoprecipitation control. Because no cells
were transfected or treated, no input control was performed. The following primary
antibodies were used for immunoblotting: rabbit or mouse anti-GFP (Abcam), mouse
anti-actin (Sigma or Abcam), rabbit anti-LC3 (Sigma), mouse or rabbit anti-HA (Abcam
or Sigma, respectively), guinea pig anti-p62 (Progen), rabbit anti-TRIM5α (Imgenex),
mouse anti-K63 type polyubiquitin (Enzo Life Sciences), and mouse anti-K48 type
polyubiquitin (Enzo Life Sciences).
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CHAPTER 5

DISCUSSION AND FUTURE IMPLICATIONS
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Objective and hypothesis
The studies presented in this dissertation were designed and implemented to investigate
the species-specific variation in the involvement of autophagy during HIV-1 infection.
We hypothesized that HIV would escape autophagy in a host model for productive
infection and, conversely, that HIV would not be able to escape autophagy in a host
model where productive infection does not occur. We found that the HIV factor Nef
inhibits autophagic maturation in the human macrophage, thus allowing the virus to
escape degradation and elimination by autophagy. We also showed that the rhesus
macaque restriction factor RhTRIM5α allows the rhesus macaque to utilize autophagy to
eliminate HIV, an ability that is lost in the human cells studied. Finally, we explored a
recently revealed role for both human and rhesus TRIM5α in regulating innate immunity
through induction of autophagy and identify a previously an association of K63 type
polyubiquitin in complex with TRIM5α (specifically, RhTRIM5α). Here we discuss the
future implications of the research presented in this dissertation.

Chapter 2 Summary
In Chapter 2, we tested the specific hypothesis that autophagy could be manipulated to
eliminate HIV in the human macrophage. Contrary to our hypothesis, we show that: (i)
autophagy is essential in maintaining optimal viral yields from macrophages, (ii)
autophagy promotes biogenesis of HIV by supporting the processing of HIV structural
proteins, (iii) elimination of HIV by autophagic degradation is inhibited by HIV
regulatory protein Nef, and (iv) Nef specifically inhibits acidification of autophagosomes
through an as yet described mechanism requiring its 174DD175 motif. These findings lead
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us to conclude that HIV is capable of circumventing elimination by autophagy in the
human macrophage, one of two primary targets for HIV infection, thus allowing the virus
to establish a productive infection in macrophages for significance to the development of
AIDS.

HIV-1 factor Nef protects the virus from autophagic degradation in the human
macrophage
To investigate the role of autophagy in human macrophages, we tested whether
pharmacological induction of autophagy during a stable HIV infection reduces the
replication rate. Unexpectedly, we found that treatment of cells with an autophagy
inducer increased the amount of virus released into the culture media. We went on to
show that this effect was due to the viral protein Nef; Nef was inhibiting the maturation
stage of autophagy thereby preventing elimination of the virus by autophagic
degradation.

Not only is the autophagy pathway altered by HIV during infection, but it also appears to
be hijacked by HIV to assist in the processing of viral structural proteins required for
proper virion assembly. We showed that when essential autophagy factor Beclin 1 is
knocked down in these cells, processing of HIV Gag is decreased. How exactly Nef
blocks the maturation stage of autophagy is not yet clear, but the experiments outlined in
Chapter 2 suggest that Nef may either alter the preference of Beclin 1 for one complex
versus another (initiation versus maturation or maturation inhibiting [marked by the
presence of Rubicon] versus maturation promoting [marked by the presence of
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UVRAG]), redirect Beclin 1 from the maturation complex to lysosomes for degradation
(discussed in the following paragraph), disrupt acidification of lysosomes directly by
interacting with the V1 subunit of the vacuolar ATPase, or act through altering the
membrane preference of hVPS34 in some way that disrupts maturation. As far as the
first scenario (altering Beclin 1 complex preference), Nef may, for example, prevent
Beclin 1 from associating with UVRAG, thereby decreasing Beclin 1's bioavailability for
association within the maturation complex, while stabilizing its association within the
initiation complex.

Alternatively, Nef may stabilize association of Beclin 1 with

Rubicon, resulting in a decrease in the available pool of Beclin 1 that can associate with
UVRAG. Both of these possible mechanisms would result in the down-regulation of
autophagic maturation.

Interestingly, we found that Nef's ability to inhibit maturation of autophagy requires its
174

DD175 motif. This is the same motif known to interact with the recruitment factor AP-

2, as well as the V1 subunit of the vacuolar H+ ATPase, during clathrin-mediated
endocytosis of surface CD4 [28-30]. Nef's ability to interact with both, AP-2 and the
vacuolar H+ ATPase, allows Nef to mediate the endocytosis of CD4 from the plasma
membrane. Once CD4 is endocytosed from the plasma membrane, Nef then interacts
with β-COP through its

154

EE155 motif, which allows Nef to direct CD4 containing

endosomes to lysosomes for degradation.

Thus, one could imagine a mechanism

whereby Nef down-regulates the Beclin 1 maturation complex (typically associated with
membrane as well) in the same manner as CD4 down-regulation, thereby disrupting
autophagic maturation. Similarly, Nef may also be capable of pulling in vast amounts of
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plasma membrane and directing it to autophagosomes to support biogenesis at different
time points than those tested here.

Finally, studies on the origin of autophagic membrane have shown possible involvement
of at least three sources including plasma membrane, endoplasmic reticulum, and
mitochondria [31, 157-160]. The origin of the membrane may be of significance for
pathogens requiring autophagic structures for biogenesis.

Perhaps it may even be

possible to identify the particular source of membrane by identifying certain organellespecific markers assembled into or associated with viral or microbial pathogens. This
may lead to greater understanding of the requirements for microbial biogenesis, revealing
therapeutic targets for intervention.

Chapter 3 Summary
Here we tested the hypothesis that the rhesus macaque restriction factor TRIM5α could
restrict HIV by targeting it to autophagy for degradation. We show that: (i) RhTRIM5α
targets HIV to autophagy for elimination from the cell and (ii) restriction by RhTRIM5α
requires a physical interaction with the autophagy machinery. These findings lead us to
conclude that in the rhesus macaque, autophagy and HIV are still coupled, thus
preventing HIV from establishing a productive infection and abrogating the ability of the
virus to develop into AIDS.
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RhTRIM5α can direct HIV capsid to autophagy for degradation
In order to determine if autophagy is the primary target for viral clearance by
RhTRIM5α, we used a combination of pharmacological inhibitors and genetic
manipulation to test the ability of RhTRIM5α to restrict HIV while the autophagy
pathway was impaired. We found that autophagy is required for restriction of HIV in the
presence of RhTRIM5α, as inhibiting autophagy in either HA-RhTRIM5α stably
expressing HeLa cells or FRhK4 monkey cells impaired the ability of HIV capsid protein
p24 to be degraded. Furthermore, we identified autophagy proteins, LC3 and p62,
associating with RhTRIM5α and HIV p24 in the presence of RhTRIM5α, while not in the
absence of RhTRIM5α (only p62 was investigated here).

Interaction of RhTRIM5α with p62 might reveal something about the mechanism by
which RhTRIM5α restricts HIV.

P62, already found in complex with other TRIM

proteins [75, 161] and recently with RhTRIM5α in another study [152], was first
discovered in protein aggregates where autophagic clearance of these aggregates was
impaired.

Originally, p62 was reported to traffic proteins to the proteasome for

degradation [64], but due to the intimate synergism between the proteasome and the
autophagosome, it is often difficult to distinguish between these two processes. Studies
where the effects of the proteasome have been controlled for demonstrate that the effect
of p62 is to shuttle cargo into the autophagosome, not the proteasome [66, 68, 69, 71].

The specific action of p62 is revealed in studies of neurodegenerative diseases that show
that p62 promotes aggregate formation of misfolded proteins [12, 66, 162]. Therefore, it
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is hypothesized by myself and others that p62 promotes aggresome formation through the
formation of a scaffold enveloping misfolded proteins or other items, then directs the
formation of nascent autophagic membrane around these structures [162, 163]. In the
case of HIV-1 where RhTRIM5α is present, p62 would form around the RhTRIM5α-HIV
capsid complex (consisting of HIV core covered by a network of RhTRIM5α oligomers,
inner to the p62 shell) and direct autophagic membrane formation around these encased
incoming core particles (Fig. 5.1). Assuming that this is the case, it will be important to
explore ways of re-establishing the physical link between HIV core and p62 in human
cells.

Even though human TRIM5α cannot specifically recognize HIV-1 capsid, studies have
shown that it does have slight restrictive capability, as demonstrated when human
TRIM5α is overexpressed [40]. One feature of overexpression of either TRIM5α is that
these proteins distribute in the cells in punctate structures, called cytoplasmic bodies [48].
Literature that describes the activity of these structures shows that these dynamic bodies
do not impair restriction of HIV by rhesus TRIM5α, but instead enhance its ability to
restrict [48]. Therefore, cytoplasmic body formation by either TRIM5α likely represents
a pre-autophagic structure with consequences for non-specific capture and clearance of
HIV. It would be interesting to see if cytoplasmic body formation, which does not
normally exist at endogenous expression levels in monkey cells, is induced in response to
infection with HIV.

Results from this experiment might suggest that artificially

promoting cytoplasmic body formation of human TRIM5α in vivo is enough to result in
physiologically relevant levels of HIV restriction.
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Figure 5.1. Model of RhTRIM5α-mediated autophagic recognition and capture of HIV core.
The HIV core particle is recognized and coated by RhTRIM5α oligomers, which in turn are
recognized by the autophagy adaptor p62 and LC3. Association with these autophagy factors allows
the autophagic membrane to form around the HIV core, resulting in capture by the autophagy
machinery and subsequent degradation.

Chapter 4 Summary
In the final study presented here, we hypothesized that TRIM5α could induce autophagy,
thereby promoting the antiviral response during infection. We show that: (i) TRIM5αs
can induce autophagy in the absence of infection and (ii) TRIM5αs interact with the
autophagic machinery, including the autophagy adaptor p62 and an autophagy
targeting/signaling tag, K63 polyubiquitin. These findings suggest a role for both species
variants of TRIM5α in the innate arm of the immune system through an ability to induce
autophagy.

TRIM5α may induce autophagy as part of the innate immune response
Previous literature has shown that RhTRIM5α is capable of mediating its own
polyubiquitination through the E3 ubiquitin ligase activity of its RING domain [50], but
the specific type has never been investigated. Additionally, studies have shown that both
the RING and B-box 2 domains influence the rate of protein turnover and subcellular
distribution [48, 164]. Specifically, it was shown that disruption of the RING domain
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results in an increase in the size of cytoplasmic bodies, with an overall decrease in diffuse
cytoplasmic staining, while disruption of the B-box 2 domain results in an impaired
ability of the RhTRIM5α protein to form cytoplasmic bodies (as seen by fluorescence
microscopy) [48, 164]. Furthermore, disruption of either the RING or the B-box 2
domains results in significantly impaired restriction [40, 48].

In the context of

autophagy, it may be that the B-box 2 domain controls the ability of TRIM5α to form
pre-autophagic inclusion bodies (i.e. cytoplasmic bodies; pre-requisite to autophagic
recognition), while the RING domain is required for subsequent recognition and
clearance by autophagy.

Studies on the formation of pre-autophagic inclusion bodies show that the structures are
enriched with p62 [12, 66, 162], while others have shown that they can also be enriched
in K63 type polyubiquitin [165-167]. Kah Leong Lim explains the K63 phenotype best,
“K63-linked polyubiquitin is the most consistent enhancer of inclusion formation.
Moreover, K63 ubiquitin-modified inclusions are preferentially cleared by autophagy”
[68]. One of the best autophagic adaptor proteins recognizing K63 type polyubiquitin is
p62 [64], although NBR1 (another autophagy adaptor protein, similar to p62) has also
been shown to have a strong preference for K63 type polyubiquitin as well [168].
Notably, studies on neurodegenerative diseases, particularly Huntington's disease, have
shown that p62-enriched inclusion bodies induce the upregulation of autophagy [12,
169].
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Because the study outlined in Chapter 3 shows that RhTRIM5α associates with p62 and
because it is already known that both human and rhesus TRIM5αs, when overexpressed,
are capable of distributing in the cell as "cytoplasmic bodies", very closely resembling
p62 pre-autophagic inclusion bodies, I considered the possibility that overexpressing
either human or rhesus TRIM5α (thus, artificially promoting inclusion body formation,
i.e. cytoplasmic bodies) would be able to stimulate autophagy. When this was tested,
indeed this was the case. Next, knowing that TRIM5α is capable of ubiquitination, the
possibility that it mediates induction of autophagy through K63 type polyubiquitination
was tested. In a co-immunoprecipitation experiment, K63 type polyubiquitin was found
to associate with purified RhTRIM5α in immunoprecipitates. Conversely, when the blot
was stripped and re-probed for K48, no K48 was seen. These results suggest a preference
for K63 type polyubiquitin by TRIM5α and may reveal the type of self-ubiquitination
mediated by the TRIM5α RING domain.

Taken together, our results suggest a general model of RhTRIM5α restriction (Fig. 5.2):
RhTRIM5α acts as a pattern recognition receptor for the HIV capsid lattice (the intricate
molecular structure of the HIV core particle), allowing the indirect K63
polyubiquitination of HIV-1 capsid, thereby forcing viral core into pre-autophagic
inclusion bodies capable of being recognized and captured by p62 for autophagymediated degradation and clearance from the cell.

Furthermore, cytoplasmic body

formation of either human or rhesus TRIM5α, either artificially induced or as a result of
association with the HIV capsid, simultaneously acts as a signal inducing the
upregulation of autophagy in a K63 type polyubiquitin-dependent manner.

90

Figure 5.2. Model of RhTRIM5α-mediated K63 type polyubiquitin-dependent recognition and
capture of HIV core by the autophagy machinery. The HIV core particle is recognized and coated
by RhTRIM5α oligomers. RhTRIM5α then self-ubiquitinates with K63 type polyubiquitin, forcing
RhTRIM5α-HIV capsid complexes into large inclusion bodies (not shown here) that are recognized
by the ubiquitin binding domain (UBA) of p62 and promoted by its dimerization domain (PB1). P62
then (through its LC3 binding domain [LIR]) directs the formation of autophagic membrane around
these inclusion bodies, trapping and degrading HIV core particles.

Support for the idea that TRIM5α might upregulate autophagy as a result of K63 type
polyubiquitination comes from a recent paper showing that TRIM5α does indeed
generate K63 type polyubiquitin chains, which then induce innate immune signaling
(specifically, activator protein 1 (AP-1) and nuclear factor kappa B (NFκB) signaling)
through transforming growth factor-beta-activating kinase 1 (TAK1) to upregulate the
general antiviral response (and likely also autophagy [170]) [171].

Together, these studies suggest that promoting cytoplasmic body formation of
endogenous human TRIM5α could result in autophagy induction as an innate immune
response to viral infection. This could be tested pharmacologically through the treatment
of cells with IFNβ. The use of type I interferons to stimulate an increase in endogenous
TRIM5α expression has had been previously reported [77-79]. If the treatment of cells
with IFNβ could overexpress HuTRIM5α enough to form cytoplasmic bodies, then
autophagy should be induced and non-specific capture and clearance of HIV may occur.
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These results would be significant because they would suggest a prophylactic or
therapeutic treatment for individuals immediately after exposure to HIV-1 through the
HuTRIM5α-mediated induction of autophagy with IFNβ.
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APPENDIX A
Supplemental material
Kyei et al., http://www.jcb.org/cgi/content/full/jcb.200903070/DC1
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Figure A1. Diminished autophagy in cells subjected to Atg7 and Beclin 1 knockdowns and
transmission, and immunoelectron microscopy analysis of HIV profiles in macrophages. (A and B)
Atg7 and Beclin 1 knockdowns inhibit autophagy in U937 cells. U937 cells were cotransfected with GFPLC3 and scrambled control, Beclin 1 siRNA, Atg7 siRNA, and LC3 puncta (A) quantified (B) in cells
stimulated for autophagy. Similar data were obtained for two different autophagy induction stimuli
(starvation and IFNγ). Data indicate means; error bars indicate ±SEM; **, P < 0.01; *, P < 0.05. (C and D)
Transmission and immunoelectron micrograph HIV profiles in macrophages. (C) An enlarged area from
Fig. 2.2B showing a membranous compartment with HIV virions (black arrow) and clathrin-coated pit
budding from the profile (next to the scale bar) that is indicative of the plasma membranous nature of the
plasma membranous profile. This is in keeping with findings of HIV in membranous domains contiguous
with the plasma membrane [114, 116, 117]. (D) Immunoelectron micrographs of HIV-containing profiles
labeled with p24 (enhanced immunogold).
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Figure A2. Comparison of LC3 forms in whole cell lysate versus LC forms associated with
membranes, control for autophagy induction in cells during acute rapamycin treatment, and effects
of Nef on accumulation of LC3 puncta. (A) Comparison of LC3 forms in whole cell lysate versus LC
forms associated with membranes. Immunoblots with LC3 antibody of whole cell lysate and membrane
fractions purified as described for the gradient shown in Fig. 2.2D. Not that the whole cell lysate displays
both the unlipidated form LC3 I and the lipidated form LC3 II. Membrane fractions, identical to
preparations shown in Fig. 2.2D, display only LC3 II. (B-D) Autophagy induction is operational in cells
used to detect HIV yield-enhancing effects of acute rapamycin treatment. (B) U937 were treated with 50
μg/ml rapamycin for 2 h and immunoblotted for LC3 and actin. (C) U937 cells were transfected with GFPLC3 and treated with rapamycin with or without 3MA for 2 h. (D) Quantification of GFP-LC3 puncta in B.
Data indicate means; error bars indicate ±SEM. *, P < 0.05; †, P > 0.05; n = 3. (E and F) Nef causes
accumulation of LC3 puncta. (E) U937 were transfected with GFP-LC3 along with Nef-DsRed2 or
DsRed2. The data in A are similar to those in Fig. 2.4A, and are included to show additional cells, as dual
versus single transfected cells were not found in the same field to allow comparisons by capturing a single
field of view. (F) U937 cells were transfected with Nef-Myc and GFP-LC3, and immunostained with an
antibody against Nef. The images in B are included to show additionally that GFP-LC3 puncta
accumulation was independent of DsRed2, as they were detected in cells transfected with Nef-Myc.
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Figure A3. Inhibition of autophagic proteolysis by Nef, intracellular localization of Nef, and the role
of Nef motif 174DD175 for Nef-dependent increase in LC3 II levels. (A) Nef inhibits autophagic
proteolysis. RAW264.7 macrophages, used as the only established autophagic proteolysis system in
macrophages [124], were transfected with DsRed2 or Nef-DsRed2 for 48 h. Cells were induced for
autophagy by starvation and autophagic proteolysis of stable polypeptides radiolabeled with [3H] leucine
measured and expressed as the percentage of radiolabeled leucine released; n = 3. Data indicate means;
error bars indicated ± SEM. *, P < 0.05. (Material and methods) RAW264.7 macrophages were
transfected with DsRed2 and Nef-DsRed2 plasmids, seeded at 7 x 104 cells/well, and then incubated for 24
h in DME with [3H] leucine as described previously [124]. Cells were washed and incubated in unlabeled
DME to allow degradation of short-lived proteins as described previously[124]. Cells were then washed
three times for 10 min and incubated for 4 h in either complete DME medium or Earle's Balanced Salt
Solution. TCA precipitation of the media fraction, cell lysis, and measurement of the percentage of leucine
release was performed as described previously for autophagic proteolysis quantification [172]. Baseline
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degradation of stable proteins in nonliver cells normally converts 0.5% per 1 h (2% per 4 h) of the total
radioactivity incorporated into macromolecules into TCA-soluble form; autophagy induction normally
increases this rate by 50-200%. (B-F) Intracellular localization of Nef relative to mTOR, 2xFYVE-GFP,
and autophagy markers Atg7, Atg12, and Beclin 1. (B and C) Macrophages were transfected with NefDsRed2 for 24 h and immunostained for mTOR or cotransfected with 2xFYVE-GFP, then confocal images
were taken. (B) No colocalization is seen between Nef and mTOR (TOR, as previously described [173,
174], shows significant nuclear localization, augmented upon TOR inhibition under certain conditions
[174]). (C) Partial but distinct colocalization is evident between Nef and 2xFYVE-GFP. 2xFYVE-GFP is
a probe for phosphatidylinositol 3-phosphate, a phosphoinositide generated by hVPS34, the PI3K that
complexes with Beclin 1 in regulation of autophagy. (D-F) Macrophages were transfected with NefDsRed2, and endogenous autophagy proteins Atg7, Atg12, and Beclin 1 (Atg6) were revealed by
immunofluorescence. (G) Nef motif 174DD175 is but G2A motif is not required for a Nef-dependent increase
in LC3 II levels. 293T cells were transfected with the wild-type HIV-1 Nef fusion with GFP or the mutants
G2ANefGFP, 154EE-QQ155NefGFP, and 174DD-AA175NefGFP for 48 h, and LC3 II levels were determined
by immunoblotting. Note that in this experiment, Nef mutant and wild-type expression levels were
adjusted to more equal levels than in Fig. 2.7B.
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Table A1. HIV molecular clones, virusesa, viral preparationsb, and usec
______________________________________________________________________________________
Construct
Reference or source
Comment
______________________________________________________________________________________
pMSMBA
pMSMBA-Vpu-null
HIVΔNef

Callahan et al., 1998 [175]
McBride and Panganiban, 1996 [176]
Valentin et al., 1998 [177]

Same as NL4-3Δenv
Same as NL4-3ΔenvΔvpu
NL4-3ΔenvΔNef - GFP replaces Nef
in this clone
E. Freed, National Cancer Institute
NA
HIV-1NLAD8
SF162
Pelchen-Matthews et al., 2003 [112]
Full-length HIV virus
Barre-Sinoussi et al., 1983 [145];
CXCR4 co-receptor specific (T cell
HIVLAI
Nguyen et al., 1994 [146]
tropic)
______________________________________________________________________________________
NA, not applicable.
a

HIV clones and viruses [145, 146]. The HIV-1 NL4-3 molecular clones pMSMBA and its derivative
pMSMBA-Vpu-null have been described previously [175, 176]. GFP-HIV-Nef-null has been described
previously [177]. DsRed2 and Nef-DsRed2 (from K. Collins, University of Michagan, Ann Arbor, MI) are
derivatives of DsRed2 (Clontech Laboratories, Inc.) with reduced spontaneous aggregation, and have been
described previously [178]. The intracellular localization of Nef-DsRed2 is similar to that shown for NefGFP [179] or immunostained Nef [134]; Nef-DsRed2 shows biological properties indistinguishable from
untagged Nef when tested for effects on MHC class I [178]. Other plasmids were p2xFYVE-EGFP from
H. Stenmark (The Norwegian Radium Hospital, Oslo, Norway), pEGFP-LC3, and tandem RFP-GFPLC3from T. Yoshimori (OsakaUniversity, Japan). Nef-GFP and associated mutants are derivatives of
pcNEFsg25GFP. SF162 macrophage-tropic virus [112] was obtained through the National Institutes of
Health (NIH) AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of
Allergy and Infectious Diseases, NIH: SF162, No. 276.

bVirus generation and isolation. Replication-competent HIV-1NLAD8 was generated by transfections of
HEK293T cells with the proviral construct pNLAD8. Preparations of pMSMBA and HIV-Nef-null virus
(pseudotyped with the envelope glycoprotein of the VSV-G were obtained as cleared supernatants of 293T
cells 48 h after calcium phosphate cotransfection; viral infections were carried out as described previously
[130]. For isolation of VLPs, cell supernatants were harvested, spun down at 14,000 rpm for 30 s to
remove any cells, and layered (500 μl) on to 400 μl of 20% sucrose in PBS, then centrifuged at 20,000 g for
90 min at 4°C.
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GLOSSARY

adaptive immunity - A collection of cellular mechanisms evolved to combat microbial
pathogens during sustained infection. Activation of adaptive immunity typically results
in antibody production.

aggresome - A macromolecular cluster of proteins, not necessarily misfolded,
distributing in microscopy images as large foci within the cell.

AIDS (acquired immunodeficiency syndrome) - Symptomatic disease associated with
HIV-1 infection in humans characterized by an impaired immune system due to, among
other things, depleted CD4+ T cells levels.

autolysosome (autophagolysosome) - The mature double membrane vacuole of
autophagy consisting of an autophagosome fused with a lysosome, where the contents are
in a state of degradation.

autophagy (n.) - [autophagic (adj.)] A cellular homeostatic process by which
cytoplasmic components, including aggregated proteins, portions of cytosol and
organelles, whole organelles, and intracellular pathogens, are degraded in a double
membrane vacuole through fusion with lysosomes. Consisting of the following three
types: macroautophagy, microautophagy, and chaperone-mediated autophagy.
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autophagosome - The fundamental organelle of the autophagy pathway, a closed double
membrane vacuole.

bafilomycin A1 - An inhibitor of autophagic maturation, specifically interfering with
proper vacuolar ATPase formation, which results in improper acidification of
autophagosomes.

Beclin 1 - A protein with undescribed activity that regulates autophagy initiation and
maturation through association with various autophagy factors.

endocytosis - A process where extracellular materials are internalized in a single
membrane vesicle. Trafficking involves a group of proteins commonly referred to as the
ESCRT machinery. Acquisition of materials commonly requires utilization of clathrin.

HIV (human immunodeficiency virus) -

capsid, HIV - Structural portion of the HIV viral particle that encloses and protects
the HIV genomic material, consisting of a complex of p24 structural protein. Exists in
a Fullerene shaped structure.

core, HIV - The entire capsid structure, including cellular and other viral proteins
believed to be incorporated with the capsid protein p24.
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p24 - HIV structural protein which forms the capsid of HIV.

HuTRIM5α (human TRIM5α) - Ortholog of rhesus TRIM5α without anti-HIV-1
activity. Can restrict N-tropic murine leukemia virus however. Contains the same
domains as RhTRIM5α (see RhTRIM5α for an explanation of the domains).

hVPS34 - A class III PI3 kinase capable of generating PI3P, believed to be essential for
autophagic membrane formation, typically found on complex with Beclin 1.

innate immunity - A collection of cellular response mechanisms evolved to combat
microbial pathogens immediately after infection. Activation of innate immunity typically
results in cytokine production.

K48 polyubiquitin - Individual ubiquitin proteins linked to each other through their
lysine residue at position 48.

K63 polyubiquitin - Individual ubiquitin proteins linked to each other through their
lysine residue at position 63.

LC3 - An autophagy marker commonly used in autophagy research. Exists in the cell in
two forms: (i) the LC3 I (15kDa) form, which is unlipidated and free in the cytosol, and
(ii) the LC3 II (18kDa) form, which is conjugated to phosphatidylethanolamine (PE) and
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is only found on autophagic membrane. Conversion from the LC3 I form to the LC3 II
form indicates the rate of autophagic flux.

lysosome - An acidic vesicle also containing proteases used during endocytic and
autophagic digestion.

mTOR (mammalian target of rapamycin) - Inhibits Ulk1 activity through
phosphorylation.

multivesicular body - An endosome were vesicles bud internally from the membrane
into the lumen of the endosome resulting in a multivesicular appearance. Thought to be
important for sorting endosomal contents for recycling prior to fusion with and
degradation by lysosomes.

Nef - HIV regulatory protein that potently enhances the pathogenicity of the virus.
Previously shown to be involved in enhancing infectivity and egress of individual viral
particles, as well as altering cellular pathways.

p150 - The catalytic subunit of hVPS34.

p62 (also called sequestosome 1) - Autophagic adaptor
protein involved in recognition of cytoplasmic targets,
Figure G1. p62 domains.

typically aggregated proteins, for autophagy. Specifically
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recognizes the polyubiquitin tag of proteins through its UBA domain and associates with
LC3 through it LIR domain. PB1 domain allows dimerization with itself and other
autophagy adaptors. The ZZ type zinc finger is involved in other signaling functions of
p62.

phagophore - The immature double membrane structure of autophagy prior to fusion and
formation of the autophagosome.

rapamycin - An inducer of autophagy, specifically inhibits mTOR suppression of
autophagy initiation and results in an elevated rate of autophagic flux.

restriction factor - A host cellular protein capable of inhibiting a virus at a particular
stage in the virus's life cycle.

RhTRIM5α (rhesus TRIM5α) - Potent early
entry restriction factor to HIV-1 expressed in
rhesus macaque tissues. The RING domain of

Figure G2. RhTRIM5α domains.

RhTRIM5α has E3 ubiquitin ligase activity. The B-box 2 domain is required for HIV
restriction. The coiled-coil domain is the site of RhTRIM5α oligomerization. The SPRY
domain is the site of specific HIV capsid recognition.
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VSV-G pseudotyped HIV - An engineered HIV virion consisting of an HIV core within
a vesicular stomatitis virus (VSV) glycoprotein (G) envelope. Typically generated by cotransfection of plasmids encoding HIVΔenv and VSV-G protein in a producer cell.
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